Document:

TECHNOLOGY
INTEGRATION AGREEMENT

 

This
Technology Integration Agreement (this “Agreement”) is made effective as of 1 January 2019 (the “Effective Date”)
by and between Alliance Pharma Solutions, a Delaware limited liability company, having an office at 3840 Land O’ Lakes Blvd.,
Land O’ Lakes, FL 34639, or its nominee, (“Alliance”), and SyncHealth MSO, LLC, a Delaware limited liability
company, having an office at 2107 Gunn Hwy, Odessa, FL 33556 (“SyncHealth”). SyncHealth and Alliance are each referred
to herein as a “Party” or collectively as the “Parties.”

 

RECITALS:

 

WHEREAS,
Alliance and SyncHealth member PanOptic Health, LLC. Delaware limited liability company (“PanOptic”) have entered
into that certain “Contribution Agreement” dated of even date herewith, that certain “Operating Agreement of
SyncHealth LLC” dated of even date herewith and that certain “Letter Agreement” of even date herewith (collectively
with any exhibits, schedules, annex and amendments thereto, the “Transaction Documents”) pursuant to which Alliance
and PanOptic have contributed assets to SyncHealth and Alliance and PanOptic have agreed to enter into this Agreement to pursue
the Business Purpose (defined below);

 

WHEREAS,
SyncHealth is in the business of providing prescription management software known as E-Hub Services described on Schedule 1.22(g)
to the Contribution Agreement (the “SyncHealth Application”) to health care providers and pharmacies;

 

WHEREAS,
Alliance, itself and through its Affiliates, is engaged in the business of (i) providing an online platform for independent licensed
pharmacies to purchase pharmaceuticals from licensed wholesale distributors (the “Alliance Network”); (ii) wholesale
pharmaceutical sales, logistics and logistic services (“Integra Pharma Services”); and (iii) delivery of pharmaceuticals
directly to patients (the “DelivMeds Application”);

 

WHEREAS,
Alliance and SyncHealth contemplate that they wish to participate in the exchange of technology to ensure a more complete integration
of the two companies’ technologies for their respective end user customers and prospective customers (“End Users”);
and

 

WHEREAS,
pursuant to the Transaction Documents, the integration of the respective Party’s Products (defined below) will create an
integrated healthcare platform capable of driving value between prescription origination and final patient delivery under one
unified healthcare platform (collectively, the “Business Purpose”). 

 

    	 	 	 

    	 

    

 

NOW,
THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the
parties, intending to be legally bound, agree as follows:

 

	1.	Definitions.

 

	 	a.	“Affiliate”
    means any entity which controls, is controlled by, or is under common control with a Party, where “control” means
    the legal, beneficial or equitable ownership of at least a majority of the aggregate of all voting equity interests in such
    entity.
	 	 	 
	 	b.	“Effective Date” means the effective
date stated on the signature page of this Agreement, or if no effective date is stated, the date of last signature on this Agreement.
	 	 	 
	 	c.	“Initial Term” has the meaning given
in Section 6(a) (Term and Termination).
	 	 	 
	 	d.	“Intellectual Property” means any right
recognized as intellectual property in any jurisdiction worldwide, or any information or materials eligible for recognition as
intellectual property with the passage of time, filing of an application, or other event. Examples of Intellectual Property include,
without limitation, copyrights, trade secrets, patents, Marks, moral rights, the right to make a governmental application to register
or issue any of them, and the right to prosecute an infringement action in respect of any of them.
	 	 	 
	 	e.	“Mark” means a trademark, services mark,
trade name, trade dress, or similar identifying indicia.
	 	 	 
	 	f.	“Marketing
Materials” means any information or material used to market or promote a Party’s Products, whether in print, digital,
audio, video or any other form or media. Examples of Marketing Materials are, without limitation: advertisements, web content,
web banners, web links, data, test results, white papers, survey results, trade show exhibits, shirts, hats, cups, golf balls,
pens, food wrappers, and printed matter.
	 	 	 
	 	g.	“Renewal
Term” has the meaning given in Section 6(a) (Term and Termination).
	 	 	 
	 	h.	“SyncHealth
Products” means certain software products, services and projects developed and owned by SyncHealth, its Affiliates and their
licensors, as the same may be modified by SyncHealth, its Affiliates and their licensors from time to time, including without
limitation the SyncHealth Application.
	 	 	 
	 	i.	“SyncHealth
API” means (i) the application programming interface(s) (“API”) and data feeds made available by SyncHealth
under this Agreement, (ii) documentation, materials, sample code and software (including any human-readable programming instructions)
relating to an API or data feed, (iii) data and information, including SyncHealth’s proprietary directory of hyperlinks
to the SyncHealth Application provided to the Alliance Products through an API or data feed (“SyncHealth API Data”);
and (iv) the credentials assigned to Alliance or the Alliance Products by SyncHealth.

 

    	 	 	 

    	 

    

 

	 	j.	“Term” means the Initial
Term and any Renewal Term, collectively.
	 	 	 
	 	k.	“Alliance API” means (i) the application
programming interface(s) (“API”) and data feeds made available by Alliance under this Agreement, (ii) documentation,
materials, sample code and software (including any human-readable programming instructions) relating to an API or data feed, (iii)
data and information, including Alliance’s proprietary directory of hyperlinks to Alliance Products, provided to the SyncHealth
Application through an API or data feed (“Alliance API Data”); and (iv) the credentials assigned to SyncHealth or
the SyncHealth Application by Alliance.
	 	 	 
	 	l.	“Alliance Products” means certain software
products, services and projects developed and owned by Alliance, its Affiliates and their licensors, as the same may be modified
by Alliance, its Affiliates and their licensors from time to time, including without limitation the Alliance Platform, the Integra
Pharma Services and the DelivMeds Application.

 

	2.	Grant.
    

 

	 	a.	Alliance
    hereby grants SyncHealth a non-exclusive right to market, promote and demonstrate the Alliance Products to End Users. SyncHealth
    hereby grants Alliance the exclusive right to market, promote and demonstrate the SyncHealth Products to End Users. Unless
    the appropriate documents and provisions are mutually agreed upon by the parties, neither Party shall, however, make any offer
    to or enter into any agreement with a potential End User with respect to the other Party’s products, but will refer
    potential End Users to the other Party. Each Party shall have access to and is entitled to provide a potential End User with
    official Marketing Material regarding the other Party’s products.
	 	 	 
	 	b.	Each
    Party shall use reasonable efforts to keep the other Party generally informed of its marketing and promotion activities relating
    to the other Party’s products. The Parties may only use marketing and promotional material provided by the other Party
    when performing marketing and promotion activities relating to the other Party’s products. The Parties are aware of
    the fact that:

 

	 	i.	each
    Party is marketing and promoting their respective products and services on a nation-wide basis in the United States; and 
	 	 	 
	 	ii.	Alliance
    has engaged or may in the future engage other partners in any territory to perform the same or similar services as set out
    in this Agreement. SyncHealth agrees that it is not now and will not in the future engage other partners in any territory
    to perform the same or similar services as set out in this Agreement. Each Party shall exercise its rights under this Agreement
    in accordance with the terms and conditions contained herein and shall conduct itself with the skill and care of a reputable
    firm or independent contractor within the Party’s field of business. Neither Party shall make representations or warranties
    on behalf of the other Party, represent that it has any authority to assume or create any obligation, expressed or implied,
    on behalf of the other Party, or represent that the other Party is responsible, in contract or otherwise, beyond those obligations
    specifically undertaken by the other Party in this Agreement.

 

    	 	 	 

    	 

    

 

	3.	License.

 

	 	a.	Alliance
    hereby grants SyncHealth a non-exclusive, non-transferable, royalty free, revocable license during the Term of this Agreement
    to access the Alliance Products to be made available to SyncHealth by Alliance, at Alliance’s discretion, solely for
    the purpose of evaluating, testing, certifying, marketing, promoting and demonstrating the Alliance Products solely in conjunction
    with SyncHealth’s Products. SyncHealth hereby grants Alliance the exclusive, transferable and sublicensable (to Affiliates,
    subcontractors and channel partners), royalty free, irrevocable license during the Term of this Agreement to access the SyncHealth
    Products to be made available to Alliance by SyncHealth, in SyncHealth’s discretion, solely for the purpose of evaluating,
    testing, certifying, marketing, promoting and demonstrating the SyncHealth Products solely in conjunction with the Alliance
    Products. Neither Party will use the other Party’s products to process any data in a production environment or otherwise
    make commercial use or offer to make commercial use of the other Party’s products.
	 	 	 
	 	b.	Subject
    to the terms and conditions of this Agreement, Alliance hereby grants to SyncHealth, and SyncHealth hereby accepts, a non-exclusive,
    non-transferable, non-sublicensable and revocable right and license during the Term to access and use the Alliance API solely
    to develop, reproduce and distribute SyncHealth Applications and incorporate the Alliance APIs into SyncHealth Applications
    for the purpose of delivering Alliance and SyncHealth Products to End Users. 
	 	 	 
	 	c.	Subject
    to the terms and conditions of this Agreement, SyncHealth hereby grants to Alliance, and Alliance hereby accepts, an exclusive,
    transferable and sublicensable (as described below) and irrevocable right and license during the Term to access and use the
    SyncHealth API solely to develop, reproduce and distribute Alliance applications and incorporate the Alliance APIs into Alliance
    Products for the purpose of delivering Alliance and SyncHealth Products to End Users. 

 

    	 	 	 

    	 

    

 

	 	d.	SyncHealth
    shall retain ownership to the SyncHealth Products and derivative works thereof and Alliance shall retain ownership of the
    Alliance Products and derivative works thereof. Nothing in this Agreement shall confer any rights in either Party’s
    intellectual property except as expressly provided for herein. Neither Party shall:

 

	 	i.	copy
    or manufacture the other Party’s products or any portion thereof; 
	 	 	 
	 	ii.	translate,
    modify, adapt, enhance, extend, decompile, dissemble or reverse engineer the other Party’s products;
	 	 	 
	 	iii.	sublicense
    or transfer the other Party’s products to any third party; 
	 	 	 
	 	iv.	export
    the other Party’s products in contravention of any applicable export regulations; 
	 	 	 
	 	v.	create,
    develop, license, acquire, use, or deploy any third-party software or services to attempt to disable license keys in the other
    Party’s products; or 
	 	 	 
	 	vi.	disclose
    the results of any benchmark test of the other Party’s products to any third party without the other Party’s prior
    written approval.

 

	 	e.	Each
    Party shall make commercially reasonable efforts to provide maintenance and support solely for the interoperability of their
    respective products in accordance with such Party’s then-current maintenance and support policy; however, no support
    for any third party, including but not limited to customers and partners, shall be provided under this Agreement. Furthermore,
    to enable each Party to exercise the rights granted in this Agreement, each Party shall make available to the other Party
    access to such Party’s partner website or portal as is necessary to fulfill this Agreement.
	 	 	 
	 	f.	The
    Products of each Party may contain or be provided with certain third-party proprietary or open source code. Such third-party
    or open source code is licensed under the terms of the applicable license conditions and/or copyright notices that can be
    found in the license file, the related documentation or other materials accompanying the products. Each Party represents that
    it will comply fully with the terms and conditions of the applicable third party or open source license terms. Neither Party
    shall use open source software in such a way as to subject any source code thereof of the other party to the provisions of
    any standards organization or open source code license which could: 

 

	 	i.	require
    or condition the use or distribution of such source code; 
	 	 	 
	 	ii.	require
    the license of any of the other Party’s products and services or any portion thereof for the purpose of making modifications
    or derivative works;
	 	 	 
	 	iii.	require
    the distribution of such source code or any portion thereof without charge; 
	 	 	 
	 	iv.	require
    or condition the disclosure, licensing or distribution of any such source code, any of the other Party’s Products and
    services or any portion thereof; or 

 

    	 	 	 

    	 

    

 

	 	v.	otherwise
    impose a limitation, restriction or condition on the right of the other Party or any of its wholly owned subsidiaries to distribute
    any of the other Party’s Products and services or any portion thereof.

 

	 	g.	In
    an abundance of caution, and without limiting the generality of any of the foregoing, the intention of the Parties is that
    all licenses and grants hereunder by SyncHealth to Alliance be exclusive and irrevocable, and all licenses and grants by Alliance
    to SyncHealth be non-exclusive and revocable. 

 

	4.	Cooperative
    Activities.

 

	 	a.	The
    Parties both agree to allocate and apply sufficient resources and qualified personnel to meet our obligations hereunder. 
	 	 	 
	 	b.	The
    Parties will provide the other Party with its current and available sales brochures and other sales literature generally made
    available to its prospects and End Users, in reasonable quantities.
	 	 	 
	 	c.	The
    Parties will provide the other Party with a profile of its Products and services. Subject to review and approval, each Party
    agrees to post the other’s profile on its public web sites (“Party Profile”). Each Party may use the other’s
    Marks for the sole purpose of the Party Profile. Any other reproduction, distribution, or use of the Marks must be approved
    in advance by the owning party.
	 	 	 
	 	d.	Each
    Party will name a designated contact for this Agreement. 
	 	 	 
	 	e.	Neither
    Party is authorized to make any representation, warranty, endorsement or guarantees concerning the other Party’s Products,
    their functionality, interoperability, or performance characteristics, except to the extent set forth in the marketing literature
    and promotional materials delivered by the other Party about the other Party’s Products.

 

	5.	Marketing.
    From time to time, each Party may participate in joint promotional and marketing activities on mutual agreement and subject
    to resource availability. From time to time the Parties may mutually agree to other cooperative obligations or amendment the
    current joint marketing activities. 

 

	 	a.	SyncHealth
    may not use or authorize the use of any Marketing Materials in connection with its activities under this Agreement other than
    those provided by Alliance or approved by Alliance in advance in writing. SyncHealth may not represent to any person orally,
    in writing, or otherwise that the Alliance Products have any features, functions, or other qualities other than those described
    in the documentation or in Alliance provided or approved Marketing Materials. Alliance may not use or authorize the use of
    any Marketing Materials in connection with its activities under this Agreement other than those provided by SyncHealth or
    approved by SyncHealth in advance in writing. Alliance may not represent to any person orally, in writing, or otherwise that
    the SyncHealth Products have any features, functions, or other qualities other than those described in the documentation or
    in SyncHealth provided or approved Marketing Materials.

 

    	 	 	 

    	 

    

 

	 	b.	Alliance
    and SyncHealth will each conduct its business in compliance with applicable law and its posted privacy policy and will market
    and sell the other Party’s Products ethically and in a manner that reflects favorably on each Party’s reputation.
    Specifically, but without limitation, Alliance and SyncHealth will comply with applicable laws as described below in Section
    14(h). Neither Party will make negative comments about the other Party or its products or services, orally or in writing,
    to any End User or Opportunity, or in any public forum.
	 	 	 
	 	c.	Each
    Party will use reasonable care to maintain the confidentiality of its user name, password or other portal access credentials.
    Each Party acknowledges that any information on the portal is Confidential Information of the other Party protected under
    Section 7.

 

	6.	Term
    and Termination.

 

		a.
	The
    initial term of this Agreement (the “Initial Term”) begins on the Effective Date and continues until the second
    anniversary of the Effective Date. Upon expiration of the Initial Term, this Agreement will automatically renew for successive
    renewal terms of one year each (each a “Renewal Term”) until either Alliance or SyncHealth gives the other a written
    notice of nonrenewal at least ninety (90) days prior to the expiration of the Initial Term, or then-current Renewal Term,
    as applicable.
	 	 	 
	 	b.	Either
    party may terminate this Agreement if the other party is in material violation of the Agreement and the violation is either
    un-curable or the party in violation fails to cure the violation within thirty (30) days of the other party’s written
    notice describing the violation in reasonable detail.
	 	 	 
	 	c.	Each
    Party’s authorization to use the other Party’s Marks are automatically terminated on termination of this Agreement
    and each Party shall immediately stop its marketing efforts.
	 	 	 
	 	d.	The
    following sections survive termination of the Agreement: Section 1 (Definitions) to the extent any defined term is used in
    another surviving section, this Section 6 (Term and Termination), Section 7 (Intellectual Property), Section 8 (Confidential
    Information), Section 9 (Limit on Liability), Section 10 (Relationship Between the Parties), Section 11 (Indemnification),
    Section 12 (Notices), Section 13 (Governing Law, Disputes), Section 14 (Miscellaneous) and any other section that by its nature
    is intended to survive expiration or termination of this Agreement.

 

    	 	 	 

    	 

    

 

	7.	Intellectual
    Property.

 

	 	a.	The
    Parties may not use the other Party’s Intellectual Property, Products and/or Application except as expressly authorized
    in this Agreement. Except for the license rights expressly granted in this Agreement, each Party continues to retain all rights
    in its Intellectual Property.
	 	 	 
	 	b.	Each
    Party may use the other Party’s Marks in accordance with Section 4(c) and otherwise authorized from such Party in writing
    from time to time. Each Party must comply with the other Party’s trademark usage guidelines published on its partner
    portal or otherwise communicated to such Party, as they may be modified from time to time. Each Party’s use of the other
    Party’s Marks is subject to the conditions and requirements of the trademark usage guidelines. SyncHealth’s license
    to use the Alliance Marks is non-exclusive, revocable, non-transferable, and non-sublicensable; conversely, Alliance’s
    license to use the SyncHealth Marks is exclusive, irrevocable, transferable and assignable to an Alliance Affiliate. Each
    Party’s license to use the other Party’s Marks automatically terminates on expiration or termination of this Agreement.
    On termination of the license to use the other Party’s Marks, such Party will immediately cease using the other Party’s
    Marks and will return or destroy all Marketing Materials bearing the other Party’s Marks as requested by such Party.
    Each Party agrees that it will not attempt to register any of the other Party’s Marks, or any name, logo or other indicia
    that is confusingly similar to a Mark of such other Party, in any jurisdiction in the world, will not use the other Party’s
    Mark in a way that suggests a general endorsement by the other Party of its activities, and will not knowingly impair the
    other Party’s Marks. Except for the rights expressly granted in this Section or a Party’s trademark usage guidelines,
    each Party retains all, right, title and interest in and to its Marks worldwide, including any non-English language version
    of the Marks. 
	 	 	 
	 	c.	The
    term “Partner Created Technology” means any of the following information or materials and all related Intellectual
    Property that are created by a Party, whether created solely or jointly with a third party, and Partner Pre-Existing Intellectual
    Property (as that term is defined below): 

 

	 	i.	an
    extension or utility designed for use with the other Party’s Products;
	 	 	 
	 	ii.	a
    tool useful in managing data processed by the other Party’s Products (such as a visualization or workflow tool);
	 	 	 
	 	iii.	a
    technology that is designed to extend or enable the other Party’s Products functionality or the use of the other Party’s
    Products; and
	 	 	 
	 	iv.	Documentation
    regarding any of the foregoing. 

 

    	 	 	 

    	 

    

 

	 	d.	SyncHealth
    will own the SyncHealth-created Partner Created Technology, subject to Alliance’s license right stated below. Alliance
    will own the Alliance-created Partner Created Technology, subject to SyncHealth’s license right stated below. “Partner
    Pre-Existing Intellectual Property” means a Party’s Intellectual Property that existed prior to the Effective
    Date of this Agreement, or that was created by such Party during the Term of this Agreement, either alone, or jointly with
    the other Party or the End User or any other person. For avoidance of doubt, neither is authorized to modify the Products
    of the other Party or create derivative works of such Products.
	 	 	 
	 	e.	SyncHealth
    hereby licenses Alliance to make, have made, use, sell, offer for sale, import, copy, reproduce, display, perform, modify,
    create derivative works, distribute, commercialize, exploit, and otherwise dispose of in any manner now known or in the future
    discovered, the SyncHealth-created Partner Created Technology on an exclusive, perpetual, royalty free, fully-paid, irrevocable,
    worldwide, unconditional, fully transferable basis. Alliance hereby licenses SyncHealth to make, have made, use, sell, offer
    for sale, import, copy, reproduce, display, perform, modify, create derivative works, distribute, commercialize, exploit,
    and otherwise dispose of in any manner now known or in the future discovered, the Alliance-created Partner Created Technology
    on a non-exclusive, perpetual, royalty free, fully-paid, revocable, worldwide, unconditional, non-transferable basis.
	 	 	 
	 	f.	Each
    Party’s use of the other Party’s Products, Marketing Materials, Marks and Confidential Information are subject
    to terms and conditions stated in other sections of this Agreement. Any information or materials provided by a Party to the
    other Party in connection with the Agreement that are not Products, Marketing Materials, Marks, or Confidential Information
    are “Other Party Materials” subject to the terms and conditions stated in this Subsection. Each Party is licensed
    to use Other Party Materials on a non-exclusive, revocable basis, solely for use in marketing and selling the Alliance and
    SyncHealth Products. Each Party may transfer and sublicense the Other Party Materials to its authorized subcontractors as
    described in Section 14(a), and if the Other Party Materials have been released on a “generally available” basis
    by such Party. Neither Party may otherwise transfer or sublicense the Other Party Materials.

 

	8.	Confidential
    Information; Personally Identifiable Information.

 

	 	a.	Information
    disclosed by a party or its Affiliates (the “Discloser”) to the other party or its Affiliates (the “Recipient”)
    regarding the Discloser’s assets, liabilities, financial results, financing plans, business strategies, pricing, discounts,
    product development plans, marketing strategies, operations, source code, technology, know-how, trade secrets, customers,
    channels, contractors, suppliers, employees and other personnel, and all other information that the Recipient should reasonably
    understand to be confidential, due to the nature of the information or the circumstances of its disclosure, is “Confidential
    Information” of discloser, regardless of the form or manner in which it is disclosed, and regardless of whether the
    information is marked or designated as confidential. Each Party acknowledges that the terms of this Agreement are Confidential
    Information of the other Party.

 

    	 	 	 

    	 

    

 

	 	b.	Information
    that would otherwise be Confidential Information under this Agreement shall not be Confidential Information if the information:
    (i) becomes publicly known through no fault of Recipient, (ii) was rightfully known by Recipient, or in Recipient’s
    possession, before Discloser’s disclosure as evidenced by Recipient’s written business records; (iii) is disclosed
    to Recipient by a third party who, to Recipient’s knowledge, acquired the information without violation of law or contract,
    and who does not have an obligation of confidentiality to Discloser with respect to the information; or (iv) is independently
    developed by Recipient without any use of, access to, or reference to the Confidential Information of Discloser as evidenced
    by Recipient’s written business records.
	 	 	 
	 	c.	The
    Recipient shall not disclose Discloser’s Confidential Information except to Recipient’s employees, and to third
    parties who need to know the information to represent or advise the Recipient with respect to the subject matter of this Agreement,
    provided that all employees and third party recipients must be bound by written confidentiality obligations covering the Confidential
    Information that are at least as stringent as those stated in this Agreement. Recipient shall not use the Confidential Information
    except in connection with the Business Purpose, the performance of its obligations or exercise of its rights under this Agreement.
    However, Recipient shall not be in violation of this Section if it discloses or uses Discloser’s Confidential Information
    to comply with a legal requirement, such as a subpoena or preservation order, or to bring or defend a claim in a adjudicatory
    proceeding, provided that Recipient has limited its disclosure to only that Confidential Information reasonably necessary
    in light of circumstances, and has given Discloser reasonable advance notice of the disclosure or use (unless such notice
    is prohibited by law). Recipient will use reasonable care to protect the Confidential Information from unauthorized use and
    disclosure. Recipient shall return or destroy the Confidential Information upon expiration or termination of this Agreement
    or earlier on Discloser’s request, provided that Recipient may retain the Confidential Information as part of its reasonable
    and customary business records. On Discloser’s request, Recipient shall certify its compliance with the preceding sentence.
    Recipient is responsible for a breach of this Section by its agents or representatives.

 

    	 	 	 

    	 

    

 

	 	d.	Notwithstanding
    anything to the contrary contained in this Agreement, with respect to any personally identifiable information that can be
    used to identify, contact, locate, or be traced back to the specific person to whom such information pertains (“PII”)
    delivered or made available to a Party under or pursuant to this Agreement, each Party agrees that:

 

	 	i.	Neither
    Party shall use, process, copy, display, publish, store or transfer the PII except for the sole purpose of carrying out its
    obligations as expressly set forth in this Agreement;
	 	 	 
	 	ii.	Each
    Party shall comply with the other Party’s data privacy and security requirements and shall prevent the unauthorized
    use, dissemination, or publication of PII by: (i) maintaining an effective information security program; (ii) keeping PII
    strictly confidential; and (iii) taking appropriate administrative, technical and physical measures to secure and protect
    the PII against unauthorized, unlawful or accidental access, disclosure, transfer, destruction, loss or alteration. Without
    limiting the generality of the foregoing, technical and organizational measures to protect PII shall include those measures
    required by all applicable local, state, national, and international laws, as well as any additional safeguards required by
    a Party. In addition, each Party is required to encrypt PII while in storage or transit and shall follow all industry best
    practices to monitor unauthorized access of PII.
	 	 	 
	 	iii.	Each
    Party must have or implement appropriate policies and procedures to ensure that: (i) unauthorized persons will not have access
    to the PII; (ii) access to the PII shall be limited to a need-to-know basis; and (iii) any employees (and subcontractors,
    if permitted pursuant to (d) below) authorized by Each Party to access the PII will be informed of its highly confidential
    nature, the limitations and procedures that apply to access and use of the PII, and that they must maintain the confidentiality
    and security of the PII.
	 	 	 
	 	iv.	Neither
    Party shall disclose or make the PII available to subcontractors without entering into an agreement in writing with the subcontractor
    whereby the subcontractor agrees to comply with and treat the PII in accordance with this Agreement. Each Party shall be responsible
    for all breaches by its employees, representatives, agents, and subcontractors.
	 	 	 
	 	v.	Each
    Party shall promptly notify the other Party in writing if such Party becomes aware of any unauthorized access to the PII,
    or if such Party becomes the subject of any governmental, regulatory, or other enforcement or private proceeding relating
    to its data handling practices.
	 	 	 
	 	vi.	When
    collecting, using, storing, transferring and otherwise processing the PII, each Party shall adhere to all applicable export
    and data privacy laws, regulations and rules, domestically and internationally, including any additional requirements communicated
    by a Party, as well as each Party’s applicable privacy policies. In the case of any legal or regulatory obligation to
    disclose the PII, each Party shall: (i) promptly notify and cooperate with the other Party; (ii) limit any disclosure to the
    minimum required by law; and (iii) to the extent possible, request that such information be kept confidential.

 

    	 	 	 

    	 

    

 

	 	vii.	Each
    Party shall provide the other Party with information regarding its privacy and data protection practices and allow the other
    Party reasonable access to audit and inspect such Party’s records, processes and facilities to determine if such Party
    is in compliance with its obligations hereunder, as well as each Party’s data privacy and security requirements, including,
    without limitation, compliance with applicable data privacy laws, regulations and rules.
	 	 	 
	 	viii.	Each
    Party shall, on termination of this Agreement or at any other time requested by the other Party, promptly and in a secure
    manner return to the other Party all PII and any copies thereof, or at such other Party’s written direction, destroy
    the PII and copies thereof (and certify that this has been done). Notwithstanding the foregoing, if applicable legislation
    or legal action prevents a Party from returning or destroying the PII, such Party shall, at no additional expense to the other
    Party, keep the PII and copies thereof secure and confidential and no longer process or otherwise use such PII, until such
    time that such legislation or legal action no longer prevents such Party from returning or destroying the PII in the manner
    required in the first sentence above.
	 	 	 
	 	ix.	Each
    Party shall promptly notify the other Party of any access requests made to such Party directly by individuals whose PII may
    have been delivered or made available to such Party pursuant to this Agreement (“data subjects”), and shall, prior
    to responding to such request, provide the other Party with copies of any such PII that such Party is processing on behalf
    of the other Party within such reasonable time limits as may be specified by the other Party. Such other Party shall have
    the option, at its discretion, to respond directly to the data subjects in lieu of such Party.
	 	 	 
	 	x.	Each
    Party must have a disaster recovery plan in effect at all times and provide copies of their disaster recovery plans to the
    other Party. Any modifications to the plans must be communicated to the other Party in writing in advance and approved by
    the other Party prior to implementation. Disaster recovery plans should include disaster avoidance and contingency plans in
    the event telephone service, Internet services, computer systems, facility power, or physical access (including employee turnover
    scenarios) to a Party’s facility is affected.
	 	 	 
	 	xi.	The
    restrictions on the use and disclosure of PII set forth herein shall survive the expiration or termination of the Agreement.
    Each Party’s obligations hereunder may not be assigned to another party without the prior written consent of the other
    Party, which consent may be withheld in such other Party’s sole discretion.

 

    	 	 	 

    	 

    

 

	9.	Limit
    on Liability. In no event shall any Party be liable for any consequential, exemplary, special, indirect, incidental or
    punitive damages, including any lost profit or lost savings even if such Party has been advised of or should be aware of the
    damages.
	 	 
	10.	Relationship
    Between the Parties. SyncHealth does not have any right of exclusivity with respect to the Alliance Products or any other
    aspect of its relationship with Alliance. Alliance may market and sell any of its products or services, including the Alliance
    Products as defined in this Agreement, either directly or via channels. SyncHealth may market and sell the Alliance Products
    only to persons who intend to use the Alliance Products for their internal business purposes. The Parties are independent
    contractors. Neither Party is the agent of the other Party; and neither Party has the authority to bind the other Party to
    any agreement.
	 	 
	11.	Indemnification.
    Each Party will indemnify and hold harmless the other Party and its employees, agents, Affiliates and suppliers from any damages,
    liabilities, judgments, fines, penalties, costs, and expenses (including reasonable attorney fees) that arise from or relate
    to (i) such Party’s breach or default of this Agreement; (ii) such Party’s gross negligence or willful misconduct;
    and (iii) any claim brought by or through the End User of the other Party’s Products, customer or other third party
    claim alleging such Party’s breach of this Agreement, violation of law, negligence, or misconduct. At an indemnified
    Party’s request, the other Party will defend an indemnified claim at such other Party’s expense.
	 	 
	12.	Notices.
    The parties address for notice purposes appear in the Agreement preamble. Notices under this Agreement must be given by electronic
    mail with a copy transmitted via first class United States mail on the date of the electronic mail notice. Notices are deemed
    given, received and effective as of the time transmitted by electronic mail, or if that time does not fall within a business
    day, as of the beginning of the first business day following the time transmitted. Notices must be given in the English language.
    A party may change its address for notice by giving notice in the manner stated in this Section.
	 	 
	13.	Governing
    Law, Disputes. This Agreement shall be governed by and interpreted under the laws of the State of Florida and the United
    States of America, as applicable, without giving effect to any conflicts of law principles that would require the application
    of the law of a different jurisdiction. The parties agree that any lawsuit or other action related to this Agreement shall
    be brought in Hillsborough County, Florida to the exclusion of any other court or tribunal, and that neither of them shall
    dispute the personal jurisdiction of such court. To the extent permitted by law, each party waives the right to a trial by
    jury in respect of any litigation arising out of or related to this Agreement or the parties’ activities in connection
    with this Agreement.

 

    	 	 	 

    	 

    

 

	14.	Miscellaneous.

 

	 	a.	Neither
    party may assign this Agreement without the prior consent of the other except that Alliance may assign the Agreement as part
    of a transaction by which it transfers all or substantially all of its assets without SyncHealth’s consent and each
    Party may sublicense its rights hereunder to its channel partners, distributors, Affiliates and subcontractors on an as-needed
    basis.
	 	 	 
	 	b.	The
    parties contemplate they shall cooperate in good faith to issue appropriate publicity consistent with program criteria.
	 	 	 
	 	c.	Unless
    otherwise expressly stated, neither Party makes any representation or warranty regarding the Products and each of them are
    provided AS IS WITH ALL FAULTS. Neither Party warrants that the other Party’s use of the Products of a Party will be
    error free, uninterrupted or completely secure. Each Party disclaims any implied or statutory warranties, such as a warranty
    of merchantability, fitness for a particular purpose, lack of malware, and non-infringement, and disclaims any warranty that
    may arise from a course of dealing.
	 	 	 
	 	d.	Except
    as otherwise provided above, this Agreement may be modified only by a written document that expressly refers to this Agreement
    by name and date and is signed by the parties. No right or remedy arising in connection with this Agreement shall be waived
    by a course of dealing between the parties, or a party’s delay in exercising the right or remedy. A party may waive
    a right or remedy only by signing a written document that expressly identifies the right or remedy waived. Unless expressly
    stated in the waiver, a waiver of any right or remedy on one occasion will not be deemed a waiver of that right or remedy
    on any other occasion, or a waiver of any other right or remedy. The pre-printed terms of the parties’ business forms
    shall be of no force or effect whatsoever.
	 	 	 
	 	e.	In
    the event one or more of the terms of this Agreement are adjudicated invalid, illegal, or unenforceable, the adjudicating
    body may either interpret this Agreement as if such terms had not been included or may reform such terms to the limited extent
    necessary to make them valid, legal or enforceable, consistent with the economic and legal incentives underlying the Agreement.
	 	 	 
	 	f.	Unless
    and to the extent specifically stated otherwise in some other section of this Agreement, there are no third-party beneficiaries
    to this Agreement. Neither party’s customers, End Users, suppliers or other person shall have the right to enforce this
    Agreement.
	 	 	 
	 	g.	This
    Agreement may be signed in multiple counterparts, which taken together shall be read as one Agreement. A signed agreement
    transmitted by facsimile, email attachment, or other electronic means shall be considered an original. The parties agree that
    electronic or digital signatures shall be given the same effect as a manual signature. The pre-printed terms on a Party’s
    purchase orders or other business forms shall have no effect whatsoever.
	 	 	 
	 	h.	The
    Parties agree to comply with all applicable laws, including, without limitation, Health Insurance Portability and Accountability
    Act of 1996 (HIPAA), the Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy (Model
    Act), the Prescription Drug Marketing Act of 1987 (PDMA), the FDA’s Guidelines for State Licensing of Wholesale Prescription
    Drug Distributors (21 CFR 205), the U.S. Foreign Corrupt Practices Act of 1977 and any other applicable laws or regulations.
    The Parties agree to comply fully with all relevant export laws and regulations, including but not limited to the U.S. Export
    Administration Regulations and regulations promulgated by the U.S. Department of the Treasury’s Office of Foreign Assets
    Control (“OFAC”), as amended from time to time (collectively, the “Export Control Laws”). The Parties
    agree not to export or re-export their respective products to any parties located in Iran, Cuba, North Korea, Syria, Sudan
    or any other countries prohibited under U.S. embargoes or sanctions programs maintained by the OFAC or otherwise prohibited
    under the Export Control Laws. SyncHealth must obtain the written permission of Alliance for any activities or licensing related
    to the Alliance Products for the countries outside the United States. This Agreement is the complete and exclusive agreement
    between the parties regarding its subject matter and supersedes and replaces in its entirety any prior or contemporaneous
    agreement or understanding regarding the subject matter of this Agreement, written or oral.

 

Remainder
of page blank; signature page follows.

 

    	 	 	 

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first referenced above.

 

	TRXADE:	SYNCHEALTH:
	 	 
	ALLIANCE
    PHARMA SOLUTIONS, LLC	SYNCHEALTH
    MSO, LLC

 

	By:	 	 	By:	PanOptic
    Health, LLC
		Surendra
    Ajjarapu	 	Its:	Manager
	Its:	Chief
    Executive Officer	 	 	 
			 	 	 
	 	 	 	By:	
	 	 	 	 	Meriam
    Ibrahim
	 	 	 	Its:	ManagerLIMITED
LIABILITY COMPANY AGREEMENT

OF

SYNCHEALTH
MSO, LLC

A
DELAWARE LIMITED LIABILITY COMPANY

 

This
Limited Liability Company Agreement of SyncHealth MSO,
LLC (the “Company”) is made and entered into effective as of 1 January 2019 (the “Effective Date”),
by and among the Members and the Company.

 

RECITALS:

 

WHEREAS,
the Company was formed as a limited liability company pursuant to the Delaware Limited Liability Company Act (6 Del. C. §
18-101, et seq., as amended and in effect from time to time, the “Act”) by filing a Certificate of Formation with
the Office of the Secretary of State of the State of Delaware;

 

WHEREAS,
reference is made to: (i) that certain Contribution Agreement dated as of even date herewith entered into by and between the Members
(the “Contribution Agreement”); (ii) that certain Technology Integration Agreement dated as of even date herewith
entered into among the Company and the Alliance Member (the “Integration Agreement”); (iii) that certain Subscription
Agreement dated as of even date herewith by and between Trxade Group, Inc. (“Trxade”) and the PanOptic Member (the
“Subscription Agreement”); (iv) that certain Shareholder Agreement dated as of even date herewith by and between Trxade
and the PanOptic Member; and (v) that certain Letter Agreement dated as of even date herewith by and between the Company, Trxade,
the Alliance Member and the PanOptic Member (the “Letter Agreement;” the Contribution Agreement, the Integration Agreement,
the Subscription Agreement, the Shareholder Agreement and the Letter Agreement, and all exhibits, schedules and annex are referred
to collectively herein as the “Transaction Documents); and

 

WHEREAS,
the parties hereto wish to effect the transactions contemplated by the Transaction Documents and commence the operation and management
of the Company on the terms set forth herein.

 

NOW,
THEREFORE, in consideration of the covenants and agreements set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE
I

DEFINITIONS

 

As
used in this Agreement, the following terms have the meanings set forth below:

 

“Act”
has the meaning set forth in the Recitals.

 

“Additional
Contribution” means, with respect to each Member, any amount contributed by such Member to the Company in excess of the
existing Contribution of such Member.

 

    	 	 	 

     

    

 

“Additional
Member” has the meaning set forth in Section 3.02(d).

 

“Adjusted
Capital Account Deficit” means, with respect to any Member, the deficit balance, if any, in such Member’s Capital
Account as of the end of the relevant Fiscal Year, after giving effect to the following adjustments:

 

(a)
credit to such Capital Account any amounts that such Member is obligated to restore pursuant to any provision of this Agreement
or is deemed obligated to restore pursuant to the penultimate sentences of Regulations Sections 1.704-2(g)(1) and 1.704-2(i)(5);
and

 

(b)
debit to such Capital Account the items described in Regulations Sections 1.704-1(b)(2)(ii)(d)(4), 1.704-1(b)(2)(ii)(d)(5) and
1.704-1(b)(2)(ii)(d)(6).

 

The
foregoing definition of Adjusted Capital Account Deficit is intended to comply with the provisions of Regulations Section 1.704-1(b)(2)(ii)(d)
and shall be interpreted consistently therewith.

 

“Affiliate”
of any Person means any Person that directly or indirectly through one or more intermediaries, Controls, is Controlled by or is
under common Control with such Person, and the term “Affiliated” shall have a correlative meaning.

 

“Agreement”
means this Limited Liability Company Agreement, including all schedules hereto, as it may be amended or restated from time to
time.

 

“Alliance
Manager” has the meaning set forth in Section 4.01(a)(ii).

 

“Alliance
Member” means Alliance Pharma Solutions, LLC, together with its respective successors and Permitted Transferees.

 

“Authorized
Representative” has the meaning set forth in Section 7.06.

 

“Bankruptcy”
of a Member means (a) the filing by a Member of a voluntary petition seeking liquidation, reorganization, arrangement or readjustment,
in any form, of its debts under Title 11 of the United States Code or any other federal or state insolvency law, or a Member’s
filing an answer consenting to or acquiescing in any such petition, (b) the making by a Member of any assignment for the benefit
of its creditors or (c) the expiration of sixty (60) days after the filing of an involuntary petition under Title 11 of the United
States Code, an application for the appointment of a receiver for the assets of a Member, or an involuntary petition seeking liquidation,
reorganization, arrangement or readjustment of its debts under any other Federal or state insolvency law, provided that the same
shall not have been vacated, set aside or stayed within such sixty-day period.

 

“Board
of Managers” has the meaning set forth in Section 4.01(a)(i).

 

“Book
Item” has the meaning set forth in Section 6.05(a)(i).

 

    	 	2	 

     

    

 

“Business
Day” means any day that is not a Saturday, Sunday or other day on which commercial banks are required or authorized by applicable
law to be closed in New York, New York.

 

“Capital
Account” has the meaning set forth in Section 3.09.

 

“Certificate”
means the Certificate of Formation of the Company as filed with the Secretary of State of the State of Delaware pursuant to the
Act as set forth in the Recitals, as it may be amended or restated from time to time.

 

“Change
of Control” means:

 

(a)
any sale, lease, exchange, or other transfer (in one transaction or series of related transactions during the twelve month period
ending on the date of the most recent sale, lease, exchange or other transfer) of all or substantially all of the assets of the
Company to any person or persons acting as a group (as determined pursuant to Treasury Regulations Section 1.409A-3(i)(5)(v)(B)
and Internal Revenue Service interpretations thereunder (a “Group”)), other than to a person or Group holding, directly
or indirectly, at least fifty percent (50%) of the total fair market value of the outstanding and issued equity interests of the
Company, as constituted immediately preceding such event or to a person or Group in which the Alliance Member and the PanOptic
Member (or any of their Affiliates) still have the right to designate a majority of the managing members, board of directors,
or other board of governance of the acquiring person or Group; or

 

(b)
the acquisition by any person or Group of more than fifty percent (50%) of the total fair market value of the outstanding and
issued equity interests in the Company, other than any event as a result of which partners or owners (or their affiliates) of
the Company, as constituted immediately preceding such event, hold greater than one-half (50%) of the total fair market value
of the outstanding and issued equity interests of the Company; provided, however, that no Change of Control under the foregoing
clause (B) shall be deemed to have occurred in the event the Alliance Member and the PanOptic Member (or any of their Affiliates)
still have the right to designate a majority of the members of the Company Board.

 

“Code”
means the Internal Revenue Code of 1986, as amended from time to time.

 

“Company”
has the meaning specified in the Preamble.

 

“Company
Business” has the meaning set forth in Section 2.05(a).

 

“Company
Expenses” has the meaning set forth in Section 4.03(a).

 

“Company
Minimum Gain” has the same meaning as “partnership minimum gain” set forth in Regulations Sections 1.704-2(b)(2)
and 1.704-2(d).

 

“Company
Register” has the meaning set forth in Section 3.01.

 

“Contribution”
means, with respect to any Member, the amount of money or fair market value of property contributed to the Company by such Member
at such time with respect to the Interests held by such Member; “Contributions” means, with respect to any Member,
the aggregate amount of money or fair market value of property contributed to the Company by such Member (or its predecessors
in interest) with respect to the Interests held by such Member.

 

    	 	3	 

     

    

 

“Control,”
“Controlled” and “Controlling” mean the possession, directly or indirectly, of the power to direct or
cause the direction of the management and policies of a Person, whether through the ownership of voting Securities, by contract
or otherwise.

 

“Depreciation”
means, for each Fiscal Year, an amount equal to the depreciation, amortization, or other cost recovery deduction allowable for
U.S. federal income tax purposes with respect to an asset for such Fiscal Year, except that (a) with respect to any asset the
Gross Asset Value of which differs from its adjusted tax basis for U.S. federal income tax purposes at the beginning of such Fiscal
Year and which difference is being eliminated by use of the “remedial method” as defined by Regulations Section 1.704-3(d),
Depreciation for such Fiscal Year shall be the amount of book basis recovered for such Fiscal Year under the rules prescribed
by Regulations Section 1.704-3(d)(2), and (b) with respect to any other asset the Gross Asset Value of which differs from its
adjusted tax basis for U.S. federal income tax purposes at the beginning of such Fiscal Year, Depreciation shall be an amount
which bears the same ratio to such beginning Gross Asset Value as the U.S. federal income tax depreciation, amortization, or other
cost recovery deduction for such Fiscal Year bears to such beginning adjusted tax basis; provided, however, that in the case of
clause (b) above, if the adjusted tax basis for U.S. federal income tax purposes of an asset at the beginning of such Fiscal Year
is zero, Depreciation shall be determined with reference to such beginning Gross Asset Value using any reasonable method selected
by the Board of Managers.

 

“Depreciation
Recapture” has the meaning set forth in Section 6.05(a)(ii)(B).

 

“Employee
Equity Plan” means any incentive equity plan or arrangement adopted by the Board of Managers for the issuance of Units to
officers, directors, managers, employees or consultants of the Company or any of its Subsidiaries.

 

“Entity”
means any general partnership, limited partnership, limited liability company, corporation, joint venture, trust, business trust,
cooperative, association or other entity.

 

“Equity
Securities” has the meaning set forth in Section 3.02(a).

 

“Excluded
Opportunity” has the meaning set forth in Section 4.06.

 

“Fiscal
Year” has the meaning set forth in Section 2.08.

 

“GAAP”
means generally accepted accounting principles in the United States.

 

“Gross
Asset Value” means, with respect to any asset, the asset’s adjusted basis for U.S. federal income tax purposes, except
as follows:

 

(a)
the Gross Asset Value of any asset contributed by a Member to the Company is the gross fair market value of such asset as determined
by the Board of Managers at the time of contribution;

 

    	 	4	 

     

    

 

(b)
the Gross Asset Value of all Company assets shall be adjusted to equal their respective gross fair market values, as determined
by the Board of Managers, as of the following times: (i) the acquisition of any additional interest in the Company by any new
or existing Member in exchange for more than a de minimis Contribution; (ii) the distribution by the Company to a Member of more
than a de minimis amount of property as consideration for an interest in the Company; (iii) the grant of an interest in the Company
(other than a de minimis interest) as consideration for the provision of services to or for the benefit of the Company by an existing
Member acting in a Member capacity, or by a new Member acting in a Member capacity or in anticipation of becoming a Member; and
(iv) the liquidation of the Company within the meaning of Regulations Section 1.704-1(b)(2)(ii)(g); provided, however, that the
adjustments pursuant to clauses (i), (ii) and (iii) above shall be made only if the Board of Managers reasonably determines that
such adjustments are necessary or appropriate to reflect the relative economic interests of the Members in the Company;

 

(c)
the Gross Asset Value of any Company asset distributed to any Member shall be adjusted to equal the gross fair market value of
such asset on the date of distribution as determined by the Board of Managers; and

 

(d)
the Gross Asset Values of all Company assets shall be increased (or decreased) to reflect any adjustments to the adjusted basis
of such assets pursuant to Section 734(b) or Section 743(b) of the Code, but only to the extent that such adjustments are taken
into account in determining Capital Accounts pursuant to Regulations Section 1.704-1(b)(2)(iv)(m) and clause (f) of the definition
of “Net Income” and “Net Loss” or Section 6.03(f); provided, however, that such Gross Asset Values shall
not be adjusted pursuant to this clause (d) to the extent the Board of Managers reasonably determines that an adjustment pursuant
to clause (b) above is necessary or appropriate in connection with a transaction that would otherwise result in an adjustment
pursuant to this subparagraph.

 

If
the Gross Asset Value of a Company asset has been determined or adjusted pursuant to clause (a) or (b) above, such Gross Asset
Value shall thereafter be adjusted by Depreciation taken into account with respect to such asset for purposes of computing Net
Income or Net Loss.

 

“Indemnified
Party” has the meaning set forth in Section 4.05(a).

 

“Initial
Public Offering” means any initial underwritten sale of common stock or other equity Securities of the Company or any Entity
that holds, directly or indirectly, all of the equity interests of the Company, pursuant to an effective registration statement
under the Securities Act filed with the Commission on Form S-1 (or a successor form) after which sale such common stock or other
equity securities are (a) listed on a national securities exchange or authorized to be quoted on an inter-dealer quotation system
of a registered national securities association and (b) registered under the Securities Exchange Act.

 

“Interest”
means the limited liability company interest represented by the Units owned by a Member in the Company at any particular time,
including the right of such Member to any and all benefits to which such Member may be entitled as provided in the Act, this Agreement,
or otherwise, together with the obligations of such Member to comply with all terms and provisions of this Agreement and the Act.

 

    	 	5	 

     

    

 

“Liquidator”
has the meaning set forth in Section 9.03(b).

 

“Manager”
has the meaning set forth in Section 4.01(a)(i).

 

“Member”
means any Person who is listed as a Member of the Company on Schedule I attached hereto, as that exhibit may be amended from time
to time, and who has been admitted as a Member of the Company pursuant to the terms and conditions of this Agreement.

 

“Member
Loan” has the meaning set forth in Section 3.08.

 

“Member
Nonrecourse Debt” has the same meaning as the term “partner nonrecourse debt” set forth in Regulations Section
1.704-2(b)(4).

 

“Member
Nonrecourse Debt Minimum Gain” means an amount, with respect to each Member Nonrecourse Debt, equal to the Member Minimum
Gain that would result if the Member Nonrecourse Debt were treated as a Nonrecourse Liability, determined in accordance with Regulations
Section 1.704-2(i)(3).

 

“Net
Income” and “Net Loss” means, for each Fiscal Year or other period, an amount equal to the Company’s taxable
income or loss for such Fiscal Year or other period, determined in accordance with Section 703(a) of the Code (for this purpose,
all items of income, gain, loss or deduction required to be stated separately pursuant to Section 703(a)(1) of the Code shall
be included in taxable income or loss) with the following adjustments (without duplication):

 

(a)
any income of the Company that is exempt from U.S. federal income tax and not otherwise taken into account in computing Net Income
or Net Loss pursuant to this paragraph, shall be added to such income or loss;

 

(b)
any expenditures of the Company described in Section 705(a)(2)(B) of the Code or treated as Section 705(a)(2)(B) of the Code expenditures
pursuant to Regulations Section 1.704-1(b)(2)(iv)(i), and not otherwise taken into account in computing Net Income or Net Loss,
shall be subtracted from such taxable income or loss;

 

(c)
in the event the Gross Asset Value of any Company asset is adjusted pursuant to clauses (b) or (c) of the definition of “Gross
Asset Value”, the amount of such adjustment shall be taken into account as gain or loss from the disposition of such asset
for purposes of computing Net Income or Net Loss;

 

(d)
gain or loss resulting from any disposition of Company property with respect to which gain or loss is recognized for U.S. federal
income tax purposes shall be computed by reference to the Gross Asset Value of the property disposed of, notwithstanding that
the adjusted tax basis of such property differs from its Gross Asset Value;

 

    	 	6	 

     

    

 

(e)
in lieu of depreciation, amortization, and other cost recovery deductions taken into account in computing such taxable income
or loss, there shall be taken into account Depreciation for such Fiscal Year, computed in accordance with the definition of “Depreciation”;

 

(f)
to the extent an adjustment to the adjusted tax basis of any Company asset pursuant to Section 734(b) or Section 743(b) of the
Code is required pursuant to Regulations Section 1.704-1(b)(2)(iv)(m) to be taken into account in determining Capital Accounts,
the amount of such adjustment shall be treated as an item of gain (if the adjustment increases the basis of the asset) or loss
(if the adjustment decreases the basis of the asset) from the disposition of the asset and shall be taken into account for purposes
of computing Net Income or Net Loss; and

 

(g)
any items which are specially allocated pursuant to the provisions of Section 6.03 shall not be taken into account in computing
Net Income or Net Loss.

 

“Nonrecourse
Deductions” has the meaning set forth in Regulations Sections 1.704-2(b)(1) and 1.704-2(c).

 

“Nonrecourse
Liability” has the meaning set forth in Regulations Section 1.704-2(b)(3).

 

“Other
Members” means: (i) with regards to a Tag-Along Sale, all the Members other than the Tag Along Seller Member; and (ii) with
regards to the Right of First Refusal, the Member who is not the Seller.

 

“PanOptic
Manager” has the meaning set forth in Section 4.01(a)(ii).

 

“PanOptic
Member” means PanOptic Health, LLC., together with its respective successors and Permitted Transferees.

 

“Partnership
Representative” has the meaning set forth in Section 7.03.

 

“Permitted
Transferee” means, with respect to each Member, (a) a corporation, limited liability company or partnership, the stockholders,
members or partners of which include only the direct or indirect stockholders, members or partners of such Member or (b) any Affiliate
of such Member.

 

“Person”
means any individual or Entity and, where the context so permits, the legal representatives, successors in interest and permitted
assigns of such Person.

 

“Preemptive
Right” has the meaning set forth in Section 3.02(b).

 

“Prime
Rate” means the highest prime rate of interest quoted from time to time by The Wall Street Journal as the “base rate”
on corporate loans at large money center commercial banks.

 

“Proposed
Issuance Notice” has the meaning set forth in Section 3.02(b).

 

“Regulations”
means the Treasury Regulations promulgated under the Code.

 

    	 	7	 

     

    

 

“Reserves”
means the amount of proceeds that the Board of Managers determines in its sole discretion is reasonably necessary to be maintained
by the Company for the purpose of paying reasonably anticipated Company Expenses, liabilities and obligations of the Company regardless
of whether such Company Expenses, liabilities and obligations are actual or contingent.

 

“Roll-Up
Transaction” has the meaning set forth in Section 13.16.

 

“Securities”
means securities of every kind and nature, including stock, interests, notes, bonds, evidences of indebtedness, options to acquire
any of the foregoing, and other business interests of every type, including interests in any Entity.

 

“Securities
Exchange Act” means the Securities Exchange Act of 1934, as amended, and applicable rules and regulations thereunder.

 

“Securities
Act” means the Securities Act of 1933, as amended, and applicable rules and regulations thereunder.

 

“Subsidiary”
means, with respect to any specified Entity, any other Entity in which such specified Entity, directly or indirectly through one
or more Affiliates or otherwise, beneficially owns at least fifty percent (50%) of either the ownership interest (determined by
equity or economic interests) in, or the voting control of, such other Entity.

 

“Substituted
Member” has the meaning set forth in Section 8.02.

 

“Tag-Along
Notice” has the meaning set forth in Section 8.04(b)(i).

 

“Tag-Along
Notice Period” has the meaning set forth in Section 8.04(b)(iii).

 

“Tag-Along
Offer” has the meaning set forth in Section 8.04(b)(ii).

 

“Tag-Along
Percentage” means a fraction, expressed as a percentage, the numerator of which is the number of Units proposed to be sold
by the Tag-Along Seller, and the denominator of which is the total number of Units held by the Tag-Along Seller at such time.

 

“Tag-Along
Portion” means, with respect to any Tagging Person in a Tag-Along Sale, the product of (a) the Tag-Along Percentage and
(b) the number of Units held by the Tagging Person immediately prior to such Tag-Along Sale.

 

“Tag-Along
Response Notice” has the meaning set forth in Section 8.04(b)(iii).

 

“Tag-Along
Right” has the meaning set forth in Section 8.04(b)(iii).

 

“Tag-Along
Sale” has the meaning set forth in Section 8.04(a).

 

“Tag-Along
Seller” has the meaning set forth in Section 8.04(a).

 

“Tagging
Person” has the meaning set forth in Section 8.04(a).

 

    	 	8	 

     

    

 

“Tax
Amount” means the excess of (a) the product of (i) the Board of Managers’ estimate of taxable income allocated to
a Member for the Fiscal Year through the end of the month in which such distribution is made, multiplied by (ii) the highest marginal
federal, state and local income tax rate applicable to individuals or corporations resident in New York, New York, the sole assets
of which are Units in effect for the Fiscal Year of the distribution, over (b) the amount of distributions previously made to
such Member pursuant to Section 5.03 during the Fiscal Year with respect to which the distribution is being made.

 

“Tax
Distribution” has the meaning set forth in Section 5.03.

 

“Transfer”
means to, directly or indirectly, transfer, sell, assign, exchange, hypothecate, pledge or otherwise encumber or dispose of.

 

“Units”
means an ownership interest in the Company, including any and all benefits to which the holder of such Unit may be entitled under
this Agreement, together with all obligations of such holder to comply with the terms and conditions of this Agreement.

 

“Unit
Percentage” of any Member at any time means a fraction, expressed as a percentage, the numerator of which is the aggregate
number of Units held by such Member at such time, and the denominator of which is the aggregate number of all Units held by all
Members at such time.

 

ARTICLE
II

ORGANIZATION

 

Section
2.01 Formation of Company. The Company has been formed pursuant to the Act. The rights and liabilities of the Members shall be
as provided for in the Act if not otherwise expressly provided for in this Agreement.

 

Section
2.02 Name. The name of the Company is “SyncHealth MSO, LLC.” The Company Business shall be conducted under such name
or under such other names as the Board of Managers may deem appropriate in compliance with applicable law. The name of the Company
and its Subsidiaries shall not include, nor shall any business of the Company or any of its Subsidiaries be conducted under any
name that includes, the name of any Member without such Member’s prior written consent, which may be withheld or withdrawn
in such Member’s sole discretion.

 

Section
2.03 Office; Agent for Service of Process. The address of the Company’s registered office in Delaware is c/o the Corporation
Service Company, 2711 Centerville Road, Suite 400, Wilmington, Delaware, 19808. The name and address of the registered agent in
Delaware for service of process are the Corporation Service Company, 2711 Centerville Road, Suite 400, Wilmington, Delaware, 19808.
The Board of Managers may change the registered office and the registered agent of the Company from time to time. The Company
shall maintain a principal place of business and office(s) at such place or places as the Board of Managers may from time to time
designate.

 

Section
2.04 Term. The Company commenced on the date of the filing of the Certificate, and the term of the Company shall continue until
the dissolution of the Company in accordance with the provisions of Article IX or as otherwise provided by law.

 

    	 	9	 

     

    

 

Section
2.05 Purpose and Scope.

 

(a)
The purpose and business of the Company (the “Company Business”) is to engage in any lawful business or activity for
which a limited liability company may be organized under the Act.

 

(b)
Except as expressly set forth in Section 2.07, the Company shall have the power to do any and all acts reasonably necessary, appropriate,
proper, advisable, incidental or convenient to or for the furtherance of the Company Business and for the protection and benefit
of the Company, and shall have, without limitation, any and all of the powers that may be exercised on behalf of the Company by
the Board of Managers pursuant to this Agreement, including pursuant to Section 2.06.

 

Section
2.06 Authorized Acts. In furtherance of the Company Business, but subject to any applicable provisions of this Agreement, the
Board of Managers, on behalf of the Company, is hereby authorized and empowered:

 

(a)
to do any and all things and perform any and all acts necessary or incidental to the Company Business;

 

(b)
to enter into, and take any action under, any contract, agreement or other instrument as the Board of Managers shall determine
to be necessary or desirable to further the objects and purposes of the Company, including contracts or agreements with any Member
or prospective Member so long as such contracts and agreements are on commercially reasonable and arm’s-length terms;

 

(c)
to open, maintain and close bank accounts and draw checks or other orders for the payment of money and open, maintain and close
brokerage, money market fund and similar accounts;

 

(d)
to hire, for usual and customary payments and expenses, consultants, brokers, attorneys, accountants and such other agents for
the Company as it may deem necessary or advisable, and authorize any such agent to act for and on behalf of the Company;

 

(e)
to incur expenses and other obligations on behalf of the Company and, to the extent that funds of the Company are available for
such purpose, pay all such expenses and obligations;

 

(f)
to borrow money, guarantee any obligation or grant a security interest in the Company’s assets, which borrowing, guarantee
or security interest shall be on such terms as the Board of Managers shall determine;

 

(g)
to bring and defend actions and proceedings at law or in equity and before any governmental, administrative or other regulatory
agency, body or commission;

 

(h)
to establish Reserves for contingencies and for any other purpose of the Company;

 

    	 	10	 

     

    

 

(i)
to prepare and file all necessary returns and statements, pay all taxes, assessments and other impositions applicable to the assets
of the Company, and withhold amounts with respect thereto from funds otherwise distributable to any Member;

 

(j)
to determine the accounting methods and conventions to be used in the preparation of any accounting or financial records of the
Company; and

 

(k)
to act for and on behalf of the Company in all matters incidental to the foregoing.

 

Section
2.07 Unanimous Manager Approvals. Notwithstanding anything to the contrary herein or otherwise, no resolutions shall be passed
or decision taken by the Board of Managers either at a meeting of the Board of Managers or its committee or by circulation in
respect of any of the following matters unless both the Alliance Manager and the PanOptic Manager shall have voted in favor of
such resolution or decision:

 

(a)
Dissolution, liquidation, reorganization merger, amalgamation, or restructuring of the Company;

 

(b)
Disposition of substantially all of the assets of the Company, except in the ordinary course of the normal business of the Company;

 

(c)
Making capital calls on the Members;

 

(d)
Changing the nature or scope of the Company Business or ceasing to carry on the Company Business, or entering into any business
other than the Company Business;

 

(e)
Amendments to the Agreement including any variations of rights attaching to Units in the Company and change in capital structure
of the Company;

 

(f)
Disagreement relating to matters of joint responsibilities of the Alliance Member and the PanOptic Member, including without limitation
those disagreements arising out of or in connection with the Transaction Documents;

 

(g)
Litigation;

 

(h)
Distributions or other distribution of any Equity Securities;

 

(i)
Transfer of any Company-owned “Intellectual Property” (as that term is defined in the Contribution Agreement) to any
third party except for, without limitation, grant of licenses for distributorship, agency, reselling arrangement and/or franchises
by the Company in the ordinary course of business;

 

(j)
Increase any Company employee salaries;

 

(k)
Incur debt in excess of $5,000.00;

 

(l)
Approve the Transfer any Units; or

 

(m)
Admit any Additional Member or Substituted Member.

 

    	 	11	 

     

    

 

Section
2.08 Fiscal Year. The fiscal year (the “Fiscal Year”) of the Company shall end on the last day of each calendar year
unless, for U.S. federal income tax purposes, another Fiscal Year is required. The Company shall have the same Fiscal Year for
U.S. federal income tax purposes and for accounting purposes.

 

ARTICLE
III

CONTRIBUTIONS

 

Section
3.01 Contributions. The Members have made Contributions as reflected in the register of the Company, which shall be maintained
by the Company in accordance with Article VII (the “Company Register”).

 

Section
3.02 Additional Contributions; Preemptive Rights; Additional Members.

 

(a)
No Member shall be required to make any Additional Contributions to the Company. In addition, no Member shall be permitted to
make any Additional Contributions to the Company without the consent of the Board of Managers. The Board of Managers, subject
to the Preemptive Right provided for in Section 3.02(b), shall have the authority to issue Units or other equity securities of
the Company, including any security or instrument convertible into equity securities of the Company (“Equity Securities”),
in such amounts and at a purchase price per Unit or other Equity Security as determined by the Board of Managers and to amend
this Agreement accordingly.

 

(b)
In the event that the Board of Managers determines to issue additional Units or other Equity Securities of the Company to any
Member or any of its Affiliates, the Board of Managers shall provide written notice thereof to the Members at least ten (10) Business
Days prior to the date of such issuance (the “Proposed Issuance Notice”). From the date of its receipt of the Proposed
Issuance Notice, each Member shall have the right (a “Preemptive Right”) to purchase such additional Units or other
Equity Securities up to an amount equal to its Unit Percentage, exercisable by notice given to the Company, which shall be an
irrevocable election, within ten (10) Business Days after its receipt of the Proposed Issuance Notice. If any Member elects not
to exercise its Preemptive Right for the full amount of Units or Equity Securities it is entitled to purchase, the other exercising
Members may elect to purchase such Units or Equity Securities on a pro rata basis by indicating such intention in the notice delivered
to the Company pursuant to this Section 3.02(b).

 

(c)
Notwithstanding anything to the contrary, if the Board of Managers determines that complying with the provisions of Section 3.02(b)
would be materially detrimental to the Company in light of the circumstances, the Company may issue additional Units or other
Equity Securities subject to the Preemptive Rights under this Section 3.02 to any Member or its Affiliates without first offering
such additional Units or other Equity Securities to any Members or complying with the procedures of Section 3.02(b), so long as
each Member receives prompt written notice of the consummation of such issuance and thereafter is given the opportunity to purchase
additional Units or other Equity Securities it would have been entitled to purchase pursuant to Section 3.02(b).

 

    	 	12	 

     

    

 

(d)
Each new member to be admitted to the Company (each an “Additional Member”) shall execute and deliver a written instrument
satisfactory to the Board of Managers, whereby such Additional Member shall become a party to this Agreement, as well as any other
documents required by the Board of Managers. Upon execution and delivery of a counterpart of this Agreement and acceptance thereof
by the Board of Managers, such Person shall be admitted as a Member. Each such Additional Member shall thereafter be entitled
to all the rights and subject to all the obligations of a Member as set forth herein.

 

Section
3.03 Interest Payments. No interest shall be paid to any Member on any Contributions. All Contributions shall be denominated in
U.S. dollars.

 

Section
3.04 Ownership and Issuance of Units.

 

(a)
The Company has issued Units to each Member in respect of the Interest of such Member. Each Member owns that number of Units as
appears next to its name on the Company Register. As of the date hereof (and after giving effect to the transactions consummated
under the Transaction Documents), Schedule I sets forth a list of all the Members and the number of Units owned by such Member.

 

(b)
The Board of Managers may issue up to One Million Units in accordance with the terms of this Agreement.

 

Section
3.05 Voting Rights. All Members shall be entitled to one vote for each Unit held by them, respectively, for any matter for which
approval of the Members is required by the Act or this Agreement and shall not be entitled to any separate class or series votes
or approval rights.

 

Section
3.06 Withdrawals. Except as explicitly provided elsewhere herein, no Member shall have any right (a) to withdraw as a Member from
the Company, (b) to withdraw from the Company all or any part of such Member’s Contributions, (c) to receive property other
than cash in return for such Member’s Contributions or (d) to receive any distribution from the Company, except in accordance
with Article V and Article IX.

 

Section
3.07 Limited Liability. Except as explicitly provided elsewhere herein or in the Act, no Member shall be liable for any debts,
liabilities or obligations of the Company whatsoever, whether arising in contract, tort or otherwise. Each of the Members acknowledges
that its Contributions are subject to the claims of any and all creditors of the Company to the extent provided by the Act and
other applicable law.

 

Section
3.08 Loans. Any Member may (with the consent of the Board of Managers), but shall not be required to, make loans to the Company
for any purpose (each a “Member Loan” and collectively, the “Member Loans”). In respect of any such Member
Loans, each lending Member shall be treated as a creditor of the Company. Such Member Loans shall be repaid as and when the Company
has funds available therefor as reasonably determined by the Board of Managers in its sole discretion, but prior to any further
distributions to the Members (other than Tax Distributions), unless otherwise agreed by such lending Members. Such Member Loans
shall bear interest and be subject to other rights and obligations as agreed to by the Member making such Member Loan and the
Board of Managers; and the principal and interest thereon shall constitute obligations of the Company. Any such Member Loans shall
not increase such Members’ Contributions or entitle such Members to any increase in such Members’ share of the profits
of the Company nor subject such Members to any greater proportion of the losses of the Company.

 

    	 	13	 

     

    

 

Section
3.09 Capital Accounts. There shall be established and maintained for each Member a separate capital account (“Capital Account”).
There shall be added to the Capital Account of each Member (a) such Member’s Contributions, (b) such Member’s distributive
share of Net Income and any item in the nature of income or gain that is specially allocated to the Member pursuant to Section
6.03, and (c) the amount of any Company liabilities assumed by such Member or which are secured by any property distributed to
such Member. There shall be subtracted from the Capital Account of each Member (a) the amount of any money, and the Gross Asset
Value of any other property, distributed to such Member, (b) such Member’s distributive share of Net Loss and any item in
the nature of loss or expense that is specially allocated to such Member pursuant to Section 6.03, and (c) the amount of any liabilities
of such Member assumed by the Company or which are secured by any property contributed by such Member of the Company. The foregoing
provision and other provisions of this Agreement relating to the maintenance of Capital Accounts are intended to comply with Regulations
Section 1.704-1(b) and shall be interpreted and applied in a manner consistent with such Regulations. In determining the amount
of any liability for purposes of this Section 3.09, there shall be taken into account Section 752(c) of the Code and any other
applicable provisions of the Code and Regulations. In the event of a Transfer in accordance with Section 8.01, the transferee
shall succeed to the Capital Account of the transferor to the extent that it relates to the transferred interest. The Capital
Account balances as of the date hereof (and after giving effect to the transactions consummated under the Conversion Agreements,
the Settlement Agreement and the Recapitalization Agreement) are set forth on Schedule I.

 

Section
3.10 Negative Capital Accounts. If any Member has a negative capital account balance (after giving effect to all contributions,
distributions and allocations for all fiscal years, including the fiscal year during which such liquidation occurs), to the extent
allowed by law, including without the limitation the Code and any Regulations, such Member shall have no obligation to make any
contribution to the capital of the Company with respect to such negative capital account balance, and such negative capital account
balance shall not be considered a debt owed to the Company, to any Member or to any other person for any purpose whatsoever.

 

Section
3.11 Repurchase or Cancellation of Units. The Units may be subject to transfer between the Members, repurchase or cancellation
as determined by the Board of Managers or pursuant to any written agreement with the Company or any of its Subsidiaries, including
pursuant to the Transaction Documents or any Employee Equity Plans and any document referred to therein.

 

    	 	14	 

     

    

 

Section
3.12 PanOptic Member Non-Compete. During the term of this Agreement and for a period of three (3) years following the termination
of this Agreement, irrespective of the time, manner, or method of such termination, the PanOptic Member, shall not, without the
express written consent of the Alliance Member and Trxade, directly or indirectly, consult with, render services to, or otherwise
participate or attempt to participate in any manner in a business or entity which competes directly or indirectly with the business
of the Company, the Alliance Member or Trxade (collectively, the “Beneficiaries”), as such activities would necessarily
harm the protectible business interests of the Beneficiaries. Given the national nature of the Beneficiaries’ businesses,
the only geographic limitation of the non-competition provision is that of the United States, and such provision shall be presumed
effective nationwide. The restrictions in this provision are necessary to allow the Beneficiaries sufficient time to protect their
legitimate interests in a business relationship established or being established with companies, clients, customers, and applicants
by affording reasonable time for the Beneficiaries to develop their personal and business relations between the Beneficiaries
and their existing potential companies, clients, customers and applicants. The PanOptic Member further acknowledges and agrees
that, by virtue of its position, its services and access to and use of the Beneficiaries’ good will, any violation by it
of any of the provisions of this Section 3.12 would cause the Beneficiaries immediate, substantial and irreparable injury for
which they have no adequate remedy at law. Accordingly, the PanOptic Member agrees and consents to the entry of an injunction
or other equitable relief by a court of competent jurisdiction restraining any violation or threatened violation of any such provisions.
The PanOptic Member waives posting by any party hereto of any bond otherwise necessary to secure such injunction or other equitable
relief. Rights and remedies provided for in this Section 3.12 are cumulative and shall be in addition to rights and remedies otherwise
available to the parties hereunder or under any other agreement or applicable law.

 

ARTICLE
IV

MANAGEMENT

 

Section
4.01 Management and Control of the Company.

 

(a)
(i) The Members have established the Company as a “managers-managed” limited liability company and have agreed to
initially designate a board of managers (the “Board of Managers”) of up to three (3) Persons to manage the Company
and its and its Subsidiaries’ business and affairs. Each of the Persons appointed to the Board of Managers is referred to
herein as a “Manager.” Each Manager shall have one vote for any matter for which approval of the Board of Managers
is required by the Act or this Agreement. The size of the Board of Managers may be increased or decreased only with the unanimous
written consent of both the Alliance Manager and the PanOptic Manager.

 

(ii)
The Alliance Member shall have the right but not the obligation to designate one of the Managers (the “Alliance Manager”),
and the PanOptic Member shall have the right but not the obligation to designate one of the Managers (the “PanOptic Manager”).
The Alliance Manager and the PanOptic Manager shall mutually agree on the third Manager (the “Independent Manager”).
The Independent Manager may only be removed by the unanimous consent of the Alliance Member and the PanOptic Member, in their
sole discretion. None of the Managers, Members and no officer, director, manager, stockholder, partner, member, employee or agent
of any Member makes any representation or warranty as to the fitness or competence of the designee of any party hereunder to serve
on the Board of Managers by virtue of such party’s execution of this Agreement or by the act of such party in designating
such designee pursuant to this Agreement.

 

    	 	15	 

     

    

 

(iii)
If at any time any Manager ceases to serve on the Board of Managers (whether due to death, resignation or removal), then only
the Member(s) responsible for the designation of such Manager pursuant to Section 4.01(a)(ii) shall be entitled to designate a
replacement for such Manager by written notice to each of the Members. The Member(s) entitled to designate a Manager under Section
4.01(a)(ii), and only such Member(s), shall be entitled to remove its or their designated Manager, at any time and from time to
time, with or without cause, in its or their sole discretion, and shall give written notice of such removal to each of the Members.
If at any time an individual serving as the Independent Manager ceases to be a Manager for any reason, the Company and each Member
agrees promptly to act in accordance with the provisions hereof to cause the election of an individual as the Independent Manager.
The Board of Managers shall initially be comprised of the individuals set forth on Schedule II, which schedule shall be updated
from time to reflect any changes to the Board of Managers pursuant to this Section 4.01.

 

(iv)
The Board of Managers shall have the exclusive right to manage and control the Company, subject to any other provisions herein
specifically requiring the approval of the Members. The Board of Managers shall have the right to perform all actions necessary,
convenient or incidental to the accomplishment of the purposes and authorized acts of the Company, as specified in Sections 2.05
and 2.06, and the Board of Managers, acting as a body pursuant to this Agreement, shall constitute a “manager” of
the Company within the meaning of the Act; provided, however, that no individual Manager shall have the authority or right to
act for or bind the Company without the requisite consent of the Board of Managers.

 

(v)
Any action, consent, approval, election, decision or determination to be made by the Board of Managers under or in connection
with this Agreement (including any act by the Board of Managers within its “discretion” under this Agreement and the
execution and delivery of any documents or agreements on behalf of the Company), shall be in the sole and absolute discretion
of the Board of Managers.

 

(vi)
Meetings of the Board of Managers are expected to be held on a quarterly basis, but in any event shall be held not less than annually,
when called by either the Alliance Member, the PanOptic Member or any member of the Board of Managers, upon not less than ten
(10) business days’ advance written notice to the Managers. Attendance at any meeting of the Board of Managers shall constitute
waiver of notice of such meeting. Additionally, a waiver of such notice in writing signed by the Manager entitled to such notice,
whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. The quorum for a meeting
of the Board of Managers shall be each of the Alliance Member and the PanOptic Member. Members of the Board of Managers may participate
in any meeting of the Board of Managers by conference telephone or similar communications equipment by means of which all persons
participating in the meeting can hear each other. All action taken by the Board of Managers shall be by a simple majority of the
voting power represented by the Managers present at a meeting thereof in person or by telephone or similar communications equipment.

 

    	 	16	 

     

    

 

(vii)
The Board of Managers may create and maintain committees, including an executive committee, an audit committee and compensation
committee.

 

(viii)
The Board of Managers may also take action without any meeting of the members of the Board of Managers (or such other governing
body) by written consent of all of the Managers setting forth the action to be approved.

 

(ix)
The Company shall pay or cause to be paid all reasonable out-of-pocket expenses incurred by each Manager in connection with traveling
to and from and attending meetings of the Board of Managers (and any committee thereof) and while conducting business at the request
of the Company.

 

(b)
No Member, in its capacity as such, shall participate in or have any control over the Company Business. Each such Member hereby
consents to the exercise by the Board of Managers of the powers conferred upon the Board of Managers by this Agreement. The Members,
in their capacities as such, shall not participate in the control, management, direction or operation of the activities or affairs
of the Company and shall not have any authority or right, in their capacities as Members of the Company, to act for or bind the
Company.

 

(c)
The Board of Managers is authorized to appoint any person as an officer of the Company who shall have such powers and perform
such duties incident to such person’s office as may from time to time be conferred upon or assigned to it by the Board of
Managers and assign in writing titles (including Chief Executive Officer, President, Vice President, Secretary and Treasurer)
to any such person. Any appointment pursuant to this Section 4.01(c) may be revoked at any time by the Board of Managers. In addition,
the Board of Managers is authorized to employ, engage and dismiss, on behalf of the Company, any Person, including an Affiliate
of any Member if on commercially reasonable and arm’s-length terms, to perform services for, or furnish goods to, the Company.
Unless the Board of Managers states otherwise, if the title is one commonly used for officers of a business corporation formed
under the Delaware General Corporation Law, the assignment of such title shall constitute the delegation to such person of the
authorities and duties that are normally associated with that office.

 

Section
4.02 Actions by the Board of Managers. Except as may be expressly limited by the provisions of this Agreement, including Section
4.01, each Manager is specifically authorized to execute, sign, seal and deliver in the name and on behalf of the Company any
and all agreements, certificates, instruments or other documents requisite to carrying out the intentions and purposes of this
Agreement and matters approved by the Board of Managers with respect to the Company.

 

    	 	17	 

     

    

 

Section
4.03 Expenses.

 

(a)
The Company shall pay for any and all expenses, costs and liabilities incurred in the conduct of the business of the Company in
accordance with the provisions hereof (collectively, “Company Expenses”), including:

 

(i)
all routine administrative and overhead expenses of the Company, including fees of auditors, attorneys and other professionals,
expenses incurred by the Partnership Representative and expenses associated with the maintenance of books and records of the Company
and communications with Members;

 

(ii)
all expenses incurred in connection with any litigation involving the Company and the amount of any judgment or settlement paid
in connection therewith;

 

(iii)
all expenses for indemnity or contribution payable by the Company to any Person, whether payable under this Agreement or otherwise
and whether payable in connection with any litigation involving the Company;

 

(iv)
all expenses incurred in connection with any indebtedness of the Company; and

 

(v)
all expenses incurred in connection with any liquidation, dissolution or winding up of the Company.

 

(b)
If the Board of Managers shall determine that funds are necessary to pay any Company Expense, then the Company may borrow funds
from any Person, including any Member in accordance with Section 3.08, for the purpose of paying such Company Expense.

 

Section
4.04 Exculpation.

 

(a)
Subject to applicable law, no Indemnified Party shall be liable, in damages or otherwise, to the Company, the Members or any of
their Affiliates for any act or omission performed or omitted by any of them in good faith (including any act or omission performed
or omitted by any of them in reliance upon and in accordance with the opinion or advice of experts, including of legal counsel
as to matters of law, of accountants as to matters of accounting, or of investment bankers or appraisers as to matters of valuation),
except (i) for any act taken by such Indemnified Party purporting to bind the Company that has not been authorized pursuant to
this Agreement or (ii) any act or omission with respect to which such Indemnified Party was grossly negligent or engaged in intentional
misconduct.

 

(b)
To the extent that, at law or in equity, any Indemnified Party has duties and liabilities relating thereto to the Company or to
any Member, such Indemnified Party acting under this Agreement shall not be liable to the Company or to any Member for its good
faith reliance on the provisions of this Agreement. The provisions of this Agreement, to the extent that they restrict the duties
and liabilities of an Indemnified Party otherwise existing at law or in equity, are agreed by the parties hereto to replace such
other duties and liabilities of such Indemnified Party, to the maximum extent permitted by applicable law.

 

    	 	18	 

     

    

 

Section
4.05 Indemnification.

 

(a)
To the fullest extent permitted by applicable law, the Company shall and does hereby agree to indemnify and hold harmless and
pay all judgments and claims against the Board of Managers or any individual Manager, any officer of the Company or the Alliance
Member in its role as Partnership Representative, any Affiliate thereof and their respective officers, directors, employees, shareholders,
partners, managers and members (each, an “Indemnified Party”, each of which shall be a third party beneficiary of
this Agreement solely for purposes of this Section 4.05 and Sections 4.04 and 4.07), from and against any loss or damage incurred
by an Indemnified Party or by the Company for any act or omission taken or suffered by such Indemnified Party in good faith (including
any act or omission taken or suffered by any of them in reliance upon and in accordance with the opinion or advice of experts,
including of legal counsel as to matters of law, of accountants as to matters of accounting, or of investment bankers or appraisers
as to matters of valuation) in connection with the Company Business, including costs and reasonable attorneys’ fees and
any amount expended in the settlement of any claims or loss or damage, except with respect to (i) any act taken by such Indemnified
Party purporting to bind the Company that has not been authorized pursuant to this Agreement or (ii) any act or omission with
respect to which such Indemnified Party was grossly negligent or engaged in intentional misconduct.

 

(b)
The satisfaction of any indemnification obligation pursuant to Section 4.05(a) shall be from and limited to Company assets (including
insurance and any agreements pursuant to which the Company, its officers or employees are entitled to indemnification) and no
Member, in such capacity, shall be subject to personal liability therefor.

 

(c)
Expenses reasonably incurred by an Indemnified Party in defense or settlement of any claim that may be subject to a right of indemnification
hereunder shall be advanced by the Company prior to the final disposition thereof upon receipt of an undertaking by or on behalf
of such Indemnified Party to repay such amount to the extent that it shall be determined upon final adjudication after all possible
appeals have been exhausted that such Indemnified Party is not entitled to be indemnified hereunder.

 

(d)
The Company shall purchase and maintain insurance on behalf of all officers, Managers and other Indemnified Parties against any
liability which may be asserted against, or expense which may be incurred by, any such Person in connection with the Company’s
activities.

 

Section
4.06 Business Opportunity. The Company and each Member renounces any interest or expectancy of the Company in, or in being offered
an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or
interest (including any matter, transaction or interest complementary to or competitive with the business of the Company or any
of its Subsidiaries) that is presented to, or acquired, created or developed by, or that otherwise comes into the possession of
any Manager or Member or any of their Affiliates or any of their respective partners, members, directors, stockholders, employees
or agents.

 

    	 	19	 

     

    

 

Section
4.07 Limitation of Liability and Fiduciary Duties. Each Manager shall have the same fiduciary duties as a member of a board of
directors of a Delaware corporation (assuming such corporation had in its certificate of incorporation a provision eliminating
the liabilities of directors as provided in Section 102(b)(7) of the General Corporation Law of the State of Delaware or any successor
provisions); provided, however, that, without limiting the generality of the foregoing, whenever the Board of Managers approves
or disapproves any action, each Manager shall be entitled to consider such Manager’s own interests or the interests of the
Member that designated such Manager. The Company and each Member agree that the provisions of this Agreement (including fiduciary
duties) or liabilities of an Indemnified Party that may otherwise exist at law or in equity, shall replace such other duties and
liabilities of such Indemnified Party.

 

ARTICLE
V

DISTRIBUTIONS

 

Section
5.01 Distributions Generally. The Members shall be entitled to receive distributions, including distributions in connection with
the liquidation, dissolution or winding up of the affairs of the Company, when and as determined by the Board of Managers, out
of funds of the Company legally available therefor, net of any Reserves, payable on such payment dates to Members on such record
date as shall be determined by the Board of Managers. All determinations made pursuant to this Article V shall be made by the
Board of Managers in its sole discretion. To the extent that the Board of Managers determines that any distributions shall be
made to the Members, such distributions shall be made in accordance with the provisions of this Article V. Notwithstanding the
foregoing, except as set forth in Section 5.03 and Section 5.04, no distributions shall be made until and unless there is no breach
or default of any Transaction Document by either the Company or PanOptic and all Gross Revenue Quotas (as defined in the Letter
Agreement) have been met.

 

Section
5.02 Distributions. Any distributions (other than Tax Distributions made pursuant to Section 5.03) to the Members shall be distributed
as follows:

 

(a)
first, to the Members in proportion to their respective Capital Accounts up to the amount of their Capital Accounts;

 

(b)
second, all remaining distributions to all Members, pro rata, in accordance with their Unit Percentage.

 

Section
5.03 Tax Distributions. Subject to the Act and to any restrictions contained in any agreement to which the Company is bound, the
Board of Managers shall make a distribution to the extent of available cash (each, a “Tax Distribution”), at the same
time and with the same priority, to the Members, pro rata, in accordance with their relative Tax Amounts, until each Member
has received an amount equal to its Tax Amount. Any such Tax Distributions shall reduce distributions otherwise made to a recipient
Member under this Agreement as set forth in Section 5.02, so that the cumulative amount distributed to each Member pursuant to
this Agreement will be the same as such Member would have received if no distributions had been made pursuant to this Section
5.03, but, for the avoidance of doubt, nothing in this sentence shall require a Member to give back any amounts previously distributed
to such Member pursuant to this Section 5.03.

 

    	 	20	 

     

    

 

Section
5.04 Distributions of Securities. The Board of Managers is authorized, in its sole discretion, to make distributions to the Members
in the form of Securities or other property received or otherwise held by the Company; provided, however, that, in the event of
any such non-cash distribution, such Securities or other property shall be valued at the fair market value thereof (as determined
by the Board of Managers) and shall be distributed to the Members in the same proportion that cash received upon the sale of such
Securities or other property at such fair market value would have been distributed pursuant to Section 5.02.

 

Section
5.05 Withholding of Certain Amounts.

 

(a)
Notwithstanding anything to the contrary contained herein, the Board of Managers may withhold from any distribution to any Member
contemplated by Sections 5.02 or 5.03 of this Agreement any amounts due from such Member to the Company or to any other Person
in connection with the Company Business to the extent not otherwise paid. Any amount withheld pursuant to this Section 5.05(a)
shall be applied by the Board of Managers to discharge the obligation in respect of which such amount was withheld.

 

(b)
Notwithstanding anything to the contrary contained herein, all amounts withheld by the Board of Managers pursuant to Section 5.05(a)
with respect to a Member shall be treated as if such amounts were distributed to such Member under this Agreement.

 

Section
5.06 Restricted Distributions. Notwithstanding anything to the contrary contained herein, the Company, and the Board of Managers
on behalf of the Company, shall not make a distribution to any Member if such distribution would violate the Act or other applicable
law.

 

Section
5.07 Withholding Tax Payments and Obligations. In the event that withholding taxes are paid or required to be paid in respect
of amounts distributed by the Company, such payments or obligations shall be treated as follows:

 

(a)
Payments by the Company. The Company is authorized to withhold from any payment made to, or any distributive share of, a Member,
any taxes required by law to be withheld, and in such event, such taxes shall be treated as if an amount equal to such withheld
taxes had been paid to the Member rather than paid over to the taxing authority.

 

(b)
Payments to the Company. If the Company receives proceeds in respect of which a tax has been withheld, the Company shall be treated
as having received cash in an amount equal to the amount of such withheld tax, and, for all purposes of this Agreement, each Member
shall be treated as having received a distribution pursuant to Section 5.02 equal to the portion of the withholding tax allocable
to such Member, as reasonably determined by the Board of Managers.

 

    	 	21	 

     

    

 

(c)
Over-withholding. Neither the Company nor the Board of Managers shall be liable for any excess taxes withheld in respect of any
Member’s interest in the Company, and, in the event of over withholding, a Member’s sole recourse shall be to apply
for a refund from the appropriate governmental authority.

 

(d)
Certain Withheld Taxes Treated as Demand Loans. Any taxes withheld pursuant to Section 5.07(a) or (b) shall be treated as if distributed
to the relevant Member to the extent an amount equal to such withheld taxes would then be distributable to such Member and, to
the extent in excess of such distributable amounts, as a demand loan payable by the Member to the Company with interest at the
lesser of (i) the Prime Rate in effect from time to time plus two percent (2%), compounded quarterly, and (ii) the highest rate
per annum permitted by law. The Board of Managers may, in its discretion, either demand payment of the principal and accrued interest
on such demand loan at any time, and enforce payment thereof by legal process, or may withhold from one or more distributions
to a Member amounts sufficient to satisfy such Member’s obligations under any such demand loan.

 

(e)
Indemnity. In the event that the Company, or the Board of Managers or any Affiliate thereof, becomes liable as a result of a failure
to withhold and remit taxes in respect of any Member, then such Member shall indemnify and hold harmless the Company, or the Board
of Managers, as the case may be, in respect of all taxes, including interest and penalties, and any expenses incurred in any examination,
determination, resolution and payment of such liability. The provisions contained in this Section 5.07(e) shall survive the termination
of the Company and the withdrawal of any Member.

 

ARTICLE
VI

ALLOCATIONS

 

Section
6.01 General Application. Except as explicitly provided elsewhere herein, the items of income, gain, loss or deduction of the
Company comprising Net Income or Net Loss for a Fiscal Year shall be allocated among the Persons who were Members during such
Fiscal Year in a manner such that the Capital Account of each Member, immediately after making such allocation, is, as nearly
as possible, equal (proportionately) to (a) the distributions that would be made to such Member pursuant to Article IX if the
Company were dissolved, its affairs wound up and its assets sold for cash equal to their Gross Asset Values, all Company liabilities
were satisfied (limited in the case of each Nonrecourse Liability to the Gross Asset Value of the assets securing such liability)
and the net assets of the Company were distributed in accordance with Section 9.03(c)(ii) to the Members immediately after making
such allocations, minus (b) such Member’s share of Company Minimum Gain and Member Nonrecourse Debt Minimum Gain, computed
immediately prior to the hypothetical sale of the assets.

 

Section
6.02 Loss Limitation. Notwithstanding anything to the contrary in Section 6.01 but subject to the last sentence of this Section
6.02, the amount of items of Company expense and loss allocated pursuant to Section 6.01 to any Member shall not exceed the maximum
amount of such items that can be so allocated without causing such Member to have an Adjusted Capital Account Deficit at the end
of any Fiscal Year, unless each Member would have an Adjusted Capital Account Deficit. All such items in excess of the limitation
set forth in this Section 6.02 shall be allocated first, to Members who would not have an Adjusted Capital Account Deficit pro
rata in proportion to their Capital Account balances, adjusted as provided in clauses (a) and (b) of the definition of “Adjusted
Capital Account Deficit,” until no Member would be entitled to any further allocation, and thereafter to the Members in
a manner determined in good faith by the Board of Managers taking into account the relative economic interests of the Members
of the Company.

 

    	 	22	 

     

    

 

Section
6.03 Special Allocations. The following special allocations shall be made in the following order and immediately prior to the
general allocations of Section 6.01:

 

(a)
Minimum Gain Chargeback. In the event that there is a net decrease during a Fiscal Year in either Company Minimum Gain or Member
Nonrecourse Debt Minimum Gain, then notwithstanding any other provision of this Article VI, each Member shall receive such special
allocations of items of Company income and gain as are required in order to conform to Regulations Section 1.704-2.

 

(b)
Qualified Income Offset. Notwithstanding any other provision of this Article VI, items of income and gain shall be specially allocated
to the Members in a manner that complies with the “qualified income offset” requirement of Regulations Section 1.704-1(b)(2)(ii)(d)(3).

 

(c)
Deficit Capital Accounts Generally. In the event that a Member has a deficit Capital Account balance at the end of any Fiscal
Year which is in excess of the sum of (i) the amount such Member is then obligated to restore pursuant to this Agreement, and
(ii) the amount such Member is then deemed to be obligated to restore pursuant to the penultimate sentences of Regulations Sections
1.704-2(g)(1) and 1.704-2(i)(5), respectively, such Member shall be specially allocated items of Company income and gain in an
amount of such excess as quickly as possible, provided that any allocation under this Section 6.03(c) shall be made only if and
to the extent that a Member would have a deficit Capital Account balance in excess of such sum after all allocations provided
for in this Article VI have been tentatively made as if this Section 6.03(c) were not in this Agreement.

 

(d)
Deductions Attributable to Member Nonrecourse Debt. Any item of Company loss or expense that is attributable to Member Nonrecourse
Debt shall be specially allocated to the Members in the manner in which they share the economic risk of loss (as defined in Regulations
Section 1.752-2) for such Member Nonrecourse Debt.

 

(e)
Allocation of Nonrecourse Deductions. Each Nonrecourse Deduction of the Company shall be specially allocated to the Members in
a manner determined in good faith by the Board of Managers taking into account the relative economic interests of the Members
of the Company.

 

(f)
Section 754 Adjustments. To the extent an adjustment to the adjusted tax basis of any Company asset, pursuant to Section 734(b)
or Section 743(b) of the Code is required, pursuant to Regulations Section 1.704-1(b)(2)(iv)(m), to be taken into account in determining
Capital Accounts, the amount of such adjustment to Capital Accounts shall be treated as an item of gain (if the adjustment increases
the basis of the asset) or loss (if the adjustment decreases such basis) and such gain or loss shall be specially allocated to
the Members in accordance with Regulations Section 1.704-1(b)(2)(iv)(m).

 

    	 	23	 

     

    

 

The
allocations pursuant to Sections 6.03(a), 6.03(b) and 6.03(c) shall be comprised of a proportionate share of each of the Company’s
items of income or gain. The amounts of any Company income, gain, loss or deduction available to be specially allocated pursuant
to this Section 6.03 shall be determined by applying rules analogous to those set forth in clauses (a) through (f) of the definitions
of “Net Income” and “Net Loss.” For purposes of determining each Member’s share of Nonrecourse Liabilities,
if any, of the Company in accordance with Regulations Section 1.752-3(a)(3), the Members’ interests in Company profits shall
be determined in the same manner as prescribed by Section 6.03(e).

 

Section
6.04 Transfer of Interest. In the event of a transfer of all or part of an interest (in accordance with the provisions of this
Agreement) or the admission of an Additional Member (in accordance with the provisions of this Agreement) the Company’s
taxable year shall close with respect to the transferring Member, and such Member’s distributive share of all items of profits,
losses and any other items of income, gain, loss or deduction shall be determined using the interim closing of the books method
under Section 706 of the Code and Regulations Section 1.706-1(c)(2)(i). Except as otherwise provided in this Section 6.04, in
all other cases in which it is necessary to determine the profits, losses, or any other items allocable to any period, profits,
losses, and any such other items shall be determined on a daily, monthly, or other basis, as determined by the Board of Managers
using any permissible method under Section 706 of the Code and the Regulations thereunder.

 

Section
6.05 Tax Allocations.

 

(a)
Section 704(b) Allocations.

 

(i)
Except as provided in Section 6.05(b) below, each item of income, gain, loss, deduction or credit for U.S. federal income tax
purposes that corresponds to an item of income, gain, loss or expense that is either taken into account in computing Net Income
or Net Loss or is specially allocated pursuant to Section 6.03 (a “Book Item”) shall be allocated among the Members
in the same proportion as the corresponding Book Item.

 

(ii)
(A) If the Company recognizes Depreciation Recapture in respect of the sale of any Company asset,

 

(1)
the portion of the gain on such sale which is allocated to a Member pursuant to Section 6.01 or Section 6.03 shall be treated
as consisting of a portion of the Company’s Depreciation Recapture on the sale and a portion of the balance of the Company’s
remaining gain on such sale under principles consistent with Regulations Section 1.1245-1, and

 

(2)
if, for U.S. federal income tax purposes, the Company recognizes both “unrecaptured Section 1250 gain” (as defined
in Section 1(h) of the Code) and gain treated as ordinary income under Section 1250(a) of the Code in respect of such sale, the
amount treated as Depreciation Recapture under Section 6.05(a)(ii)(A)(1) shall be comprised of a proportionate share of both such
types of gain.

 

    	 	24	 

     

    

 

(B)
For purposes of this Section 6.05(a)(ii), “Depreciation Recapture” means the portion of any gain from the disposition
of an asset of the Company which, for U.S. federal income tax purposes, (1) is treated as ordinary income under Section 1245 of
the Code, (2) is treated as ordinary income under Section 1250 of the Code, or (3) is “unrecaptured Section 1250 gain”
as such term is defined in Section 1(h) of the Code.

 

(b)
Section 704(c) Allocations. In the event that any property of the Company is credited to the Capital Account of a Member at a
value other than its tax basis (whether as a result of a contribution of such property or a revaluation of such property pursuant
to clause (b) of the definition of “Gross Asset Value”), then allocations of taxable income, gain, loss and deductions
with respect to such property shall be made using any method or methods selected by the Board of Managers that complies with Section
704(b) and Section 704(c) of the Code and the Regulations promulgated thereunder.

 

(c)
Credits. All tax credits shall be allocated among the Members consistent with the other allocations pursuant to this Article VI
and applicable law.

 

(d)
Capital Accounts. The tax allocations made pursuant to this Section 6.05 shall be solely for tax purposes and shall not affect
any Member’s Capital Account or share of non-tax allocations or distributions under this Agreement.

 

ARTICLE
VII

ACCOUNTING
AND TAX MATTERS

 

Section
7.01 Books and Records. At all times during the existence of the Company, the Company shall maintain, at its principal place of
business, separate books of account for the Company. Subject to reasonable confidentiality restrictions and other reasonable standards,
in each case established by the Board of Managers (including as permitted by Section 18-305(c) of the Act), each Member and its
respective agents and representatives shall be afforded access to the Company’s books and records applicable to such Member
for any proper purpose reasonably related to such Member’s Interest as a Member of the Company (as determined by the Board
of Managers in its sole discretion), at any reasonable time during regular business hours upon reasonable written notice to the
Board of Managers.

 

Section
7.02 Tax Returns. The Company shall cause the preparation and timely filing (including extensions) of all tax returns required
to be filed by the Company pursuant to the Code as well as all other required tax returns in each jurisdiction in which the Company
owns property or does business. The Company shall cause an estimated Internal Revenue Service Schedule K-1 or any successor form
to be prepared and delivered to the Members within ninety (90) days following the end of each Fiscal Year, and a final version
thereof to be delivered to the Members within sixty (60) days following the issuance of year-end, audited consolidated financial
statements for the Company (together with a copy of the Company’s federal income tax return and any relevant state K-1 tax
information). Each Member shall furnish to the Company all pertinent information in its possession that is necessary to enable
the Company’s tax returns to be prepared and filed.

 

    	 	25	 

     

    

 

Section
7.03 Tax Controversies. The Alliance Member is hereby designated the “Partnership Representative” and shall serve
as the Partnership Representative tax matters partner (as defined in the Code) and is authorized and required to represent the
Company (at the Company’s expense) in connection with all examinations of the Company’s affairs by tax authorities,
including resulting administrative and judicial proceedings. Each Member agrees that such Member shall not treat any Company item
inconsistently on such Member’s income tax return with the treatment of the item on the Company’s return and that
such Member shall not independently act with respect to tax audits or tax litigation affecting the Company, unless previously
authorized to do so in writing by the Partnership Representative, which authorization may be withheld by Partnership Representative
in its sole discretion. If the Alliance Member ceases to be the Partnership Representative for any reason, the Alliance Member
shall appoint a new Partnership Representative. The Partnership Representative may resign at any time.

 

Section
7.04 Accounting Methods; Elections. The Board of Managers shall determine the accounting methods and conventions to be used in
the preparation of the Company’s tax returns and shall make any and all elections under the tax laws of the United States
and any other relevant jurisdictions as to the treatment of items of income, gain, loss, deduction and credit of the Company,
or any other method or procedure related to the preparation of the Company’s tax returns.

 

Section
7.05 Partnership Status. The Members intend, and the Company shall take no position inconsistent with, treating the Company as
a partnership for United States federal, state and local income and franchise tax purposes prior to an Initial Public Offering
or Roll-Up Transaction.

 

Section
7.06 Confidentiality. Each Member agrees to keep confidential, and not to disclose to any Person, any matter relating to the Company
or any of its Subsidiaries, or their respective affairs (other than disclosure to such Member’s advisors responsible for
matters relating to the Company or its Subsidiaries and who need to know such information in order to perform such responsibilities
(each such Person being hereinafter referred to as an “Authorized Representative”)); provided, however, that such
Member or any of its Authorized Representatives may make such disclosure to the extent that (a) the information being disclosed
is in connection with such Member’s tax returns, (b) such disclosure is to an Affiliate of such Member or any officer, director,
shareholder or partner of such Member or its Affiliates, (c) the information being disclosed is otherwise generally available
to the public, (d) such disclosure is requested by any governmental body, agency, official or authority having jurisdiction over
such Member or (e) such disclosure, based upon the advice of legal counsel of such Member or Authorized Representative, is otherwise
required by law or statute. Prior to making any disclosure described in clause (e) of this Section 7.06, each Member shall notify
the Board of Managers of such disclosure and of such advice of counsel. Each Member shall use all reasonable efforts to cause
each of its Authorized Representatives to comply with the obligations of such Member under this Section 7.06. In connection with
any disclosure described in clauses (d) or (e) above, the disclosing Member shall cooperate with the Company in seeking any protective
order or other appropriate arrangement as the Board of Managers may request. Notwithstanding anything to the contrary, this Section
7.06 shall not prevent the Company or the Members from disclosing any matter relating to the Company or any of its Subsidiaries
or their respective affairs on a confidential basis to (i) the lenders of a Member or its Affiliates, (ii) limited partners or
prospective limited partners or investors of a Member or its Affiliates in connection with fundraising efforts or reporting requirements,
(iii) potential purchasers of interests in the Company, or (iv) financing sources to the Company or any of its Subsidiaries.

 

    	 	26	 

     

    

 

Section
7.07 Financial Reports. The Company will deliver, or will cause to be delivered, the following to each Member:

 

(a)
within 60 days after the end of each Fiscal Year, a consolidated balance sheet of the Company and its Subsidiaries as of the end
of such Fiscal Year, and consolidated statements of income, retained earnings and cash flows of the Company and its Subsidiaries
for such Fiscal Year, prepared in accordance with GAAP and setting forth in each case in comparative form the figures for the
previous Fiscal Year, all in reasonable detail and accompanied by the opinion of independent public accountants of recognized
national standing selected by the Company; and

 

(b)
within 10 days after the end of each monthly accounting period in each Fiscal Year, a consolidated balance sheet of the Company
and its Subsidiaries as of the end of each such quarterly period, and consolidated statements of income, retained earnings and
cash flows of the Company and its Subsidiaries for such period and for the current Fiscal Year to date, prepared in accordance
with GAAP (subject to normal year-end audit adjustments and the absence of notes thereto) and setting forth in comparative form
the figures for the corresponding periods of the previous Fiscal Year, all in reasonable detail and certified by the principal
financial or accounting officer of the Company.

 

ARTICLE
VIII

TRANSFERS

 

Section
8.01 Transfer in General.

 

(a)
Except as expressly contemplated by this Agreement or with the approval of the Board of Managers, for a period of Twenty Four
(24) months following the Effective Date, no Member may Transfer any of its Units except (i) pursuant to Section 8.04 in its capacity
as a Tagging Person, (ii) pursuant to Section 8.06 to its Permitted Transferees or (iii) pursuant to Section 13.16 in connection
with an Initial Public Offering or Roll-Up Transaction.

 

(b)
A permitted Transfer of Units pursuant to Section 8.01(a) shall be effective as of the date of (i) compliance with the conditions
to such transfer referred to in this Section 8.01 and (ii) admission of the Substituted Member pursuant to Section 8.02. All tax
items for the partnership taxable year of such Transfer shall be allocated between the transferor and the transferee according
to any method permissible under Section 706 of the Code (which method shall be agreed upon between the transferor and the transferee).
Distributions made before the effective date of such Transfer shall be paid to the transferor, and Distributions made after such
date shall be paid to the transferee.

 

    	 	27	 

     

    

 

(c)
Any Member who effectively Transfers any Units pursuant to this Article VIII shall cease to be a Member with respect to such Units
and shall no longer have any rights or privileges of a Member with respect to such Units (it being understood, however, that the
applicable provisions of Sections 3.07, 4.04, 4.05 and 4.07 shall continue to inure to such Person’s benefit). Nothing contained
herein shall relieve any Member who Transfers any Units in the Company from any liability or obligation of such Member to the
Company or any of its Subsidiaries or the other Members with respect to such Units that may exist on the date of such Transfer
or that is otherwise specified in the Act and incorporated into this Agreement or for any liability to the Company or any of its
Subsidiaries or any other Person for any breaches of any representations, warranties or covenants by such Member (in its capacity
as such) contained herein or in other agreements with the Company or any of its Subsidiaries.

 

(d)
In addition to any other restrictions on Transfer imposed by this Agreement, (i) no Member may Transfer any Unit (except pursuant
to an effective registration statement under the Securities Act) without first delivering to the Board of Managers, if requested,
an opinion of counsel (reasonably acceptable in form and substance to the Board of Managers) that neither registration nor qualification
under the Securities Act or applicable state securities laws is required in connection with such Transfer and (ii) no Member may
Transfer any Unit if such action would cause the Company to be taxable as a “publicly traded partnership” under the
Code. The Board of Managers may waive such opinion requirement on advice of counsel acceptable to the Board of Managers.

 

Section
8.02 Admission of Members. A Person may be admitted to the Company as a Member (i) in connection with the Transfer of any Units
to such Person as permitted under the terms of this Agreement (a “Substituted Member”) or (ii) in connection with
the issuance of new Units by the Company to an Additional Member, in each case upon executing (x) a counterpart to this Agreement,
accepting and agreeing to be bound by all of the terms and conditions hereof, or an amendment to this Agreement if so determined
in the discretion of the Board of Managers, and (y) such other documents or instruments as the Board of Managers determines are
necessary or appropriate to effect such Person’s admission as a Member and to ensure restraint on alienation consistent
with the language and intent of this Agreement. Such admission shall become effective on the date on which the Board of Managers
determines in its sole discretion that such conditions have been satisfied and when such admission is shown on the books and records
of the Company.

 

Section
8.03 Transfers in Violation of Agreement. Any Transfer or attempted Transfer in violation of this Article VIII shall be void,
and the Company shall not record such purported Transfer on its books or treat any purported transferee as the owner of any Units
subject to such purported Transfer.

 

Section
8.04 Tag-Along Rights.

 

(a)
Subject to Sections 8.01, 8.04(f) and 8.05, and after the provisions of Section 8.07 have been complied with and any transactions
entered into thereunder have been consummated, if any Member holding a Unit Percentage in excess of Fifty Percent (50%) proposes
to Transfer more than fifty percent (50%) of the Units held by it at any time (a “Tag-Along Sale”), each Other Member
may elect, at its option, to participate in the proposed Transfer in accordance with this Section 8.04 (each such electing other
Member, a “Tagging Person” and the selling Member, the “Tag-Along Seller”) for the consideration per Unit
provided by Section 8.04(b)(v).

 

    	 	28	 

     

    

 

(b)
(i) The Tag-Along Seller shall provide each other Member written notice (“Tag-Along Notice”) of the terms and conditions
of the Tag-Along Sale and offer each other Member the opportunity to participate in such Transfer and to receive the same consideration,
rights and benefits to be received by the Tag-Along Seller in accordance with this Section 8.04.

 

(ii)
The Tag-Along Notice shall identify the number of Units proposed to be Transferred by the Tag-Along Seller (a “Tag-Along
Offer”), the consideration for which the Transfer is proposed to be made, the name of the proposed Transferee and all other
material terms and conditions of the Tag-Along Offer.

 

(iii)
From the date of its receipt of the Tag-Along Notice, each Tagging Person shall have the right (a “Tag-Along Right”),
exercisable by notice (“Tag-Along Response Notice”) given to the Tag-Along Seller, which shall be an irrevocable election,
within ten (10) Business Days after its receipt of the Tag-Along Notice (the “Tag-Along Notice Period”), to request
that the Tag-Along Seller include in the proposed Transfer the number of Units held by such Tagging Person as is specified in
the Tag-Along Response Notice. Each Tagging Person shall be entitled to include in the Tag-Along Response Notice, and sell in
the Tag-Along Sale, an amount up to its Tag-Along Portion of Units and each Tag-Along Seller shall be entitled to sell the number
of Units which it proposed to be Transferred as set forth in the Tag-Along Notice (reduced, to the extent necessary, so that each
Tagging Person shall be able to include its Tag-Along Portion or the portion thereof elected to be included by such Tagging Person,
which shall not exceed its Tag-Along Portion). Each Tag-Along Response Notice shall include wire transfer instructions for payment
of the purchase price for the Units to be sold in such Tag-Along Sale. Each Tagging Person that exercises its Tag-Along Rights
hereunder shall deliver to the Tag-Along Seller, with the Tag-Along Response Notice, a limited power-of-attorney authorizing the
Tag-Along Seller to Transfer the Units of such Tagging Person to be included in the Tag-Along Sale, on the terms set forth in
the Tag-Along Notice, or, if such delivery is not permitted by applicable law, an unconditional agreement to deliver such Units
pursuant to the Tag-Along Notice, and other documents requested by the Tag-Along Seller. Delivery of the Tag-Along Response Notice
shall constitute an irrevocable acceptance of the Tag-Along Offer by such Tagging Person, and such other documents requested by
the Tag-Along Seller.

 

(iv)
If, at the end of a 90-day period after such delivery of such Tag-Along Response Notice (which 90-day period shall be extended
if any of the transactions contemplated by the Tag-Along Offer are subject to regulatory approval until the expiration of ten
(10) days after all such approvals have been received), the Tag-Along Seller have not completed the Transfer of all such Units,
on substantially the same terms and conditions set forth in the Tag-Along Notice, the Tag-Along Seller shall (A) return to each
Tagging Person the limited power-of-attorney that such Tagging Person delivered pursuant to this Section 8.04(b) and any other
documents in the possession of the Tag-Along Seller executed by the Tagging Persons in connection with the proposed Tag-Along
Sale, and (B) not conduct any Transfer of Units without again complying with this Section 8.04(b), if applicable.

 

    	 	29	 

     

    

 

(v)
In the event a Tag-Along Sale is consummated, each Member shall receive in exchange for the Units sold by such Member an amount
equal to the amount such Member would have received in respect of such Member’s sold Units if the aggregate consideration
from the Tag-Along Sale had been distributed by the Company in complete liquidation pursuant to Section 9.03; provided that, if
less than all of the Units of the Company are included in the Tag-Along Sale, then the allocation of such aggregate consideration
shall be determined by the Board of Managers in good faith based on the enterprise value of the Company, which shall be computed
based upon the consideration being paid in the Tag-Along Sale, and, if necessary, the type and amount of securities sold by the
parties in the Tag-Along Sale will be adjusted in good faith as determined by the Board of Managers.

 

(c)
Concurrently with the consummation of the Tag-Along Sale, the Tag-Along Seller shall (i) notify the Tagging Persons thereof and
(ii) remit to the Tagging Persons the total consideration for the Units of the Tagging Persons Transferred pursuant thereto, with
the cash portion of the purchase price paid by wire transfer of immediately available funds in accordance with the wire transfer
instructions in the applicable Tag-Along Response Notices.

 

(d)
If at the termination of the Tag-Along Notice Period any other Member shall not have elected to participate in the Tag-Along Sale,
such Member shall be deemed to have waived its rights under Section 8.04(a) with respect to the Transfer of its Units pursuant
to such Tag-Along Sale; provided that in no event shall such Member be deemed to have waived its rights under this Section 8.04
with respect to any future Tag-Along Sale.

 

(e)
Notwithstanding anything contained in this Section 8.04, there shall be no liability on the part of the Tag-Along Seller to the
Tagging Persons (other than the obligation to return any limited powers-of-attorney received by the Tag-Along Seller) if the Transfer
of Units pursuant to this Section 8.04 is not consummated for whatever reason. Whether to effect a Transfer of Units pursuant
to this Section 8.04 by the Tag-Along Seller is in the sole and absolute discretion of the Tag-Along Seller.

 

(f)
The provisions of this Section 8.04 shall terminate upon the occurrence of the Initial Public Offering and shall not apply to
any proposed Transfer of Units to a Permitted Transferee of the Tag-Along Seller; provided that this Section 8.04 shall apply
to a subsequent Transfer of Units by such Permitted Transferee other than as provided by this Section 8.04(f).

 

    	 	30	 

     

    

 

Section
8.05 Representations, Warranties, Covenants and Indemnities in Tag-Along Sales. Notwithstanding anything contained in Sections
8.04 in connection with a Tag-Along Sale under Section 8.04, each Tagging Person or Other Member, as applicable, shall (A) make
such representations, warranties and covenants and enter into such definitive agreements as are reasonably required in the proposed
Transfer and as are customary for transactions of the nature of the proposed Transfer, provided that if the Tagging Person or
Other Members are required to provide any representations or indemnities in connection with such Transfer (other than representations
or indemnities concerning each Tagging Person’s or Other Member’s title to its Units being Transferred and its authority,
power and right to enter into and consummate the Transfer of such Tagging Person’s or Other Member’s Units without
contravention of any law or agreement), which representations and indemnities shall not be any more comprehensive or burdensome
than that agreed to by the Tag-Along Seller(s), liability for misrepresentation or indemnity shall (as to such Tagging Person
or Other Members) be expressly stated to be several but not joint and each Tagging Person or Other Member shall not be liable
for more than its pro rata share (based on the consideration allocated to the Units Transferred, whether directly or indirectly)
of any liability for misrepresentation or indemnity, and (B) be required to bear their pro rata share (based on the consideration
allocated to the Units Transferred, whether directly or indirectly) of any escrows, holdbacks or adjustments in purchase price.

 

Section
8.06 Transfers to Permitted Transferees. A holder of Units may Transfer Units to its Permitted Transferees, subject to the conditions
that the transferring holder delivers to the Company prior written notice of a proposed Transfer specifying the class and number
of Units to be Transferred and the identity of the proposed transferee, together with documentation and appropriate certificates
showing, to the reasonable satisfaction of the Board of Managers, that the proposed transferee qualifies as such transferring
holder’s “Permitted Transferee,” and the proposed transferee executes and delivers the agreements, documents
and other instruments required pursuant to Section 8.02; provided that in case of a Transfer permitted by this Agreement by a
Member to a Permitted Transferee, the equity interest in the Permitted Transferee shall be subject to the transfer restrictions
set forth in this Article VIII, and such transferring Member shall not Transfer (directly or indirectly) any equity interest in
the Permitted Transferee without complying with the provisions of this Article VIII, in each case as if such equity interest were
“Units” hereunder (and the provisions of this proviso shall survive such Transfer).

 

Section
8.07 Right of First Refusal. Subject to the other provisions of this Agreement including
without limitation this Article VIII, in the event that a holder of Units (the “Seller”) receives a bona-fide offer
for the sale of any or all of such holder’s Units (the “Offered Securities”), the Seller shall first offer to
sell the Offered Securities to the Other Member or its designee(s) pursuant to a written notice (the “ROFR Notice”)
provided to the Other Member, which notice shall include: (i) a description of the transaction being proposed, (ii) the identity
of the offeror (“Third Party Buyer”), (iii) the purchase price proposed and the manner of payment thereof and (iv)
a term sheet setting forth the material terms and conditions of the offer and a copy of the proposed agreement, if any. Within
ten (10) days of receiving the ROFR Notice, the Other Member must either accept or decline the offer and if the Other Member neither
accepts nor declines the offer within such ten (10) day period, the offer will be considered declined. If the offer is declined
by the Other Member, (i) the Seller shall next offer to sell the Offered Securities to the Company, pursuant to a ROFR Notice
and otherwise on the terms specified in the foregoing sentence, and (ii) if the Company declines such offer, the Seller will have
the right to sell the Offered Securities to the person specified in the offer at a price and on terms and conditions no less favorable
to the Seller than the price and terms and conditions set out in the ROFR Notice. If the sale to the Third Party Buyer is not
completed within ninety (90) days after the Company declines the offer, this Section 8.08 shall again become applicable as if
the offer had not been made.

 

    	 	31	 

     

    

 

Section
8.08 Put/Call. The Put/Call provisions of the Letter Agreement are incorporated herein by
reference. Any such Transfer pursuant thereto shall be a Permitted Transfer.

 

ARTICLE
IX

DISSOLUTION; LIQUIDATION

 

Section
9.01 Dissolution. The Company shall be dissolved and its affairs wound up on the first to occur of any of the following events:

 

(a)
the decision of the Board of Managers to dissolve the Company provided however that both the Alliance Member and the PanOptic
Member must provide written consent for such Dissolution; or

 

(b)
any other event sufficient under the Act to cause the dissolution of the Company.

 

Notwithstanding
anything to the contrary, the occurrence of any event set forth in Section 18-304 of the Act (Events of Bankruptcy) with
respect to a Member (or similar Bankruptcy or insolvency event under any law or statute governing such Member) shall not cause
such Member to cease to be a Member and, upon the occurrence of such an event, the Company shall continue without dissolution.

 

Section
9.02 Final Accounting. Upon the dissolution of the Company, a proper accounting shall be made from the date of the last previous
accounting to the date of dissolution.

 

Section
9.03 Liquidation.

 

(a)
Dissolution of the Company shall be effective as of the date on which the event occurs giving rise to the dissolution and all
Members shall be given prompt notice thereof in accordance with Article XI, but the Company shall not terminate until the assets
of the Company have been distributed as provided for in Section 9.03(c). Notwithstanding the dissolution of the Company, prior
to the termination of the Company, the business, assets and affairs of the Company shall continue to be governed by this Agreement.

 

(b)
Upon the dissolution of the Company, the Board of Managers, or, if there is no Board of Managers, a Person selected by the mutual
agreement of the Alliance Member and the PanOptic Member, shall act as the liquidator (the “Liquidator”) of the Company
to wind up the Company. The Liquidator shall have full power and authority to sell, assign and encumber any or all of the Company’s
assets and to wind up and liquidate the affairs of the Company in an orderly and business-like manner.

 

    	 	32	 

     

    

 

(c)
The Liquidator shall distribute all proceeds from liquidation in the following order of priority:

 

(i)
first, to creditors of the Company (including creditors who are Members) in satisfaction of the liabilities of the Company
(whether by payment or the making of reasonable provision for payment thereof); and

 

(ii)
second, to the Members in the same manner in which distributions are made pursuant to Article V.

 

(d)
The Liquidator shall determine whether any assets of the Company shall be liquidated through sale or shall be distributed in kind.
A distribution in kind of an asset to a Member shall be considered, for the purposes of this Article IX, a distribution in an
amount equal to the fair market value of the assets so distributed as determined by the Liquidator in its reasonable discretion.

 

Section
9.04 Cancellation of Certificate. Upon the completion of the distribution of Company assets as provided in Section 9.03, the Company
shall be terminated and the person acting as Liquidator shall cause the cancellation of the Certificate in accordance with the
Act and shall take such other actions as may be necessary or appropriate to terminate the Company.

 

ARTICLE
X

AMENDMENTS

 

Section
10.01 Amendments. Except for amendments made by the Board of Managers pursuant to Section 10.02, this Agreement and the Certificate
may be modified, amended or any provision hereof or thereof waived from time to time as determined by the Board of Managers; provided,
however, that any amendment, modification or supplement that materially and adversely affects a Member or group of Members disproportionately
as compared to any other Members or group of Members shall require the prior written consent of such Member or majority-in-interest
of such group of Members, respectively, so adversely affected. No course of dealing or course of conduct between or among any
Members will be deemed effective to modify, amend or supplement any part of this Agreement or any rights or obligations of any
Member under or by reason of this Agreement.

 

Section
10.02 Amendments by the Board of Managers. The Board of Managers, without the consent or approval at any time of any Member (each
Member, by acquiring its Interest, being deemed to consent to any such amendment), may amend any provision of this Agreement or
the Certificate, and may execute, swear to, acknowledge, deliver, file and record all documents required or desirable in connection
therewith, to reflect:

 

(a)
Change in Name or Location. A change in the name of the Company or the location of the principal place of business of the Company;

 

(b)
Change in Members. The admission, dilution, substitution, termination or withdrawal of any Member in accordance with the provisions
of this Agreement;

 

(c)
Qualification to do Business. A change that is necessary to qualify the Company as a limited liability company or a company in
which the Members have limited liability;

 

    	 	33	 

     

    

 

(d)
Changes Which are Inconsequential, Curative or Required. A change that is:

 

(i)
of an inconsequential nature and does not adversely affect any Member in any material respect;

 

(ii)
necessary or desirable to cure any ambiguity or to correct or supplement any provisions of this Agreement;

 

(iii)
required or specifically contemplated by this Agreement;

 

(iv)
necessary to reflect the current Board of Managers on Schedule II following the designation of a replacement Manager by notice
to the Board of Managers and the Members in accordance with the provisions of Section 4.01(a); or

 

(v)
necessary to reflect the current Contributions and number of Units held by each Member on the Company Register, following any
change to such items in accordance with the provisions of this Agreement; and

 

(e)
Changes Under Applicable Law. A change in any provision of this Agreement which requires any action to be taken by or on behalf
of the Board of Managers or the Company pursuant to the requirements of the Act or any other applicable law if the provisions
of applicable law are amended, modified, or revoked so that the taking of such action is no longer required. The authority set
forth in this Section 10.02(e) shall specifically include the authority to make such amendments to this Agreement and to the Certificate
as the Board of Managers deems necessary or desirable in the event that the Act or any other applicable law is amended or eliminate
or change any provision now in effect.

 

ARTICLE
XI

NOTICES

 

Section
11.01 Method for Notices. All notices, requests or other communications to the Company or any Member shall be in writing (which
may include facsimile transmission) and shall be given,

 

if
to the Company, to:

 

SyncHealth,
LLC d/b/a Trxade MSO

2107
Gunn Hwy

Odessa,
FL 33556

Attention:
Chief Executive Officer

 

and
if to any Member, to the address or facsimile set forth on the Schedules to this Agreement or any other address or facsimile number
as a party may hereafter specify for such purpose to the Company.

 

    	 	34	 

     

    

 

All
such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received
prior to 5:00 p.m. in the place of receipt and such day is a business day in the place of receipt. Otherwise, any such notice,
request or communication shall be deemed not to have been received until the next succeeding business day in the place of receipt.

 

ARTICLE
XII

REPRESENTATIONS

 

Section
12.01 Investment Purpose. Each Member represents and warrants to the Company and each other Member that, as of the signing of
this Agreement:

 

(a)
if other than an individual, it is duly organized, validly existing and in good standing under the laws of the jurisdiction where
it purports to be organized;

 

(b)
unless disclosed to the Company in writing on or prior to the date hereof, it is a United States person (as defined in Section
7701(a) of the Code);

 

(c)
it has full power and authority to enter into and perform this Agreement;

 

(d)
all actions necessary to authorize the signing and delivery of this Agreement, and the performance of obligations under it, have
been duly taken;

 

(e)
this Agreement has been duly signed and delivered by a duly authorized officer or other representative of such Member (if such
Member is not an individual) and constitutes the legal, valid and binding obligation of such Member enforceable in accordance
with its terms (except as such enforceability may be affected by applicable bankruptcy, insolvency or other similar laws affecting
creditors’ rights generally, and except that the availability of equitable remedies is subject to judicial discretion);

 

(f)
no consent or approval of any other Person is required in connection with the signing, delivery and performance of this Agreement
by such Member;

 

(g)
the signing, delivery and performance of this Agreement do not violate the organizational documents of such Member (if such Member
is not an individual) or any material agreement to which such Member is a party or by which it or its assets are bound; and

 

(h)
all representations and warranties made by a Member in the Subscription Agreements are incorporated herein by reference.

 

Section
12.02 Independent Inquiry. Each Member acknowledges, agrees, represents and warrants that it has completed its own independent
inquiry and has relied fully upon the advice of its own legal counsel, accountant, financial and other advisors in determining
the legal, tax, financial and other consequences of this Agreement and the suitability of this Agreement for such Member and its
particular circumstances and has not relied upon any representations or advice by any other Member or their representatives or
advisors or the Board of Managers.

 

    	 	35	 

     

    

 

ARTICLE
XIII

GENERAL
PROVISIONS

 

Section
13.01 Governing Law. THIS AGREEMENT, THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT, AND ANY CLAIM OR CONTROVERSY
DIRECTLY OR INDIRECTLY BASED UPON OR ARISING OUT OF THIS AGREEMENT (WHETHER BASED UPON CONTRACT, TORT OR ANY OTHER THEORY), INCLUDING
ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS
OF THE STATE OF DELAWARE, WITHOUT REGARD TO ANY CONFLICT OF LAWS PROVISION THAT WOULD REQUIRE THE APPLICATION OF THE LAW OF ANY
OTHER JURISDICTION.

 

Section
13.02 Counterparts. This Agreement may be executed in counterparts (including by facsimile or other electronic transmission),
each one of which shall be deemed an original and all of which together shall constitute one and the same Agreement.

 

Section
13.03 Construction; Headings. Whenever the feminine, masculine, neuter, singular or plural shall be used in this Agreement, such
construction shall be given to such words or phrases as shall impart to this Agreement a construction consistent with the interest
of the Members entering into this Agreement. Where used herein, the term “Federal” shall refer to the U.S. Federal
government. As used herein, (a) “or” shall mean “and/or” and (b) “including” or “include”
shall mean “including without limitation.” The headings and captions herein are inserted for convenience of reference
only and are not intended to govern, limit or aid in the construction of any term or provision hereof. It is the intention of
the parties that every covenant, term, and provision of this Agreement shall be construed simply according to its fair meaning
and not strictly for or against any party (notwithstanding any rule of law requiring an Agreement to be strictly construed against
the drafting party), it being understood that the parties to this Agreement are sophisticated and have had adequate opportunity
and means to retain counsel to represent their interests and to otherwise negotiate the provisions of this Agreement. To the extent
that any ambiguity or inconsistency arises with respect to any provision(s) of this Agreement, the Board of Managers shall resolve
such ambiguity or inconsistency and such resolution shall be binding upon the Members.

 

Section
13.04 Severability. If any term or provision of this Agreement or the application thereof to any Person or circumstances shall
be held invalid or unenforceable, the remaining terms and provisions hereof and the application of such term or provision to Persons
or circumstances other than those to which it is held invalid or unenforceable shall not be affected thereby.

 

Section
13.05 Relations with Members. Unless named in this Agreement as a Member, or unless admitted to the Company as a Substituted Member
or an Additional Member as provided in this Agreement, no Person shall be considered a Member. Subject to Article VIII, the Company
and the Board of Managers need deal only with Persons so named or admitted as Members.

 

Section
13.06 Waiver of Action for Partition. Each of the Members irrevocably waives during the term of the Company any right that such
Member may have to maintain an action for partition with respect to any property of the Company.

 

    	 	36	 

     

    

 

Section
13.07 Successors and Assigns. All of the terms and provisions of this Agreement shall inure to the benefit of and be binding upon
each of the parties hereto and their respective permitted transferees, if any; provided, however, that no Transfer of the Interest
of any Member shall be made except in accordance with the provisions of Article VIII.

 

Section
13.08 Appointment of Board of Managers as Attorney-in-Fact. Each Member (including any Substituted or Additional Member) hereby
irrevocably constitutes, appoints and empowers the Board of Managers and its duly authorized officers, managers, agents, successors
and assignees, with full power of substitution and resubstitution, as its true and lawful attorneys-in-fact, in its name, place
and stead and for its use and benefit, to execute, certify, acknowledge, file, record and swear to all instruments, agreements
and documents necessary or advisable to carrying out the following:

 

(a)
any and all amendments to this Agreement that may be permitted or required by this Agreement or the Act, including amendments
required to effect the admission of Additional Members or Substituted Members pursuant to and as permitted by this Agreement or
to revoke any admission of a Member which is prohibited by this Agreement or the issuance of any Units or Equity Securities;

 

(b)
any certificate of cancellation of the Certificate that may be necessary upon the termination of the Company;

 

(c)
any business certificate, certificate of formation, amendment thereto, or other instrument or document of any kind necessary to
accomplish the Company Business;

 

(d)
all conveyances and other instruments or documents that the Board of Managers deems appropriate or necessary to effectuate or
reflect the dissolution, liquidation or winding-up of the Company pursuant to the terms of this Agreement;

 

(e)
compliance with Sections 8.04;

 

(f)
all conveyances and other instruments or documents that the Board of Managers deems appropriate or necessary to effectuate or
reflect the conversion, contribution or other actions contemplated by Section 13.16; and

 

(g)
all other instruments that may be required or permitted by law to be filed on behalf of the Company and that are not inconsistent
with this Agreement.

 

The
Board of Managers shall not take action as attorney-in-fact for any Member which would in any way increase the liability of the
Member beyond the liability expressly set forth in this Agreement or which would diminish the substantive rights of such Member.
Each Member authorizes such attorneys-in-fact to take any further action which such attorneys-in-fact shall consider necessary
or advisable in connection with any of the foregoing, hereby giving such attorneys-in-fact full power and authority to do and
perform each and every act or thing whatsoever necessary or advisable to be done in and about the foregoing as fully as such Member
might or could do if personally present, and hereby ratifying and confirming all that such attorneys-in-fact shall lawfully do
or cause to be done by virtue hereof. The appointment by each Member of the Board of Managers and its duly authorized officers,
agents, successors and assigns with full power of substitution and resubstitution, as aforesaid, as attorneys-in-fact shall be
deemed to be a power coupled with an interest in recognition of the fact that each of the Members under this Agreement shall be
relying upon the power of the Board of Managers and such officers, managers, agents, successors and assigns to act as contemplated
by this Agreement in such filing and other action by it on behalf of the Company. The foregoing power of attorney shall survive
the Transfer by any Member of the whole or any part of its Interests hereunder. The foregoing power of attorney may be exercised
by such attorneys-in-fact by listing all of the Members executing any agreement, certificate, instrument or document with the
signatures of such attorneys-in-fact acting as attorneys-in-fact for all of them.

 

    	 	37	 

     

    

 

Section
13.09 Entire Agreement. This Agreement constitutes the entire agreement among the Members and between the Members with respect
to the subject matter hereof and supersedes any agreement (including the Initial Agreement) or understanding, including any term
sheets or letters of intent, entered into as of a date prior to the date hereof among or between them with respect to such subject
matter.

 

Section
13.10 No Third Party Beneficiaries. It is understood and agreed among the parties that this Agreement and the covenants made herein
are made expressly and solely for the benefit of the parties hereto, and that, with the exception of Trxade, no other Person,
other than an Indemnified Party pursuant to Sections 4.04, 4.05 and 4.07, shall be entitled or be deemed to be entitled to any
benefits or rights hereunder, nor be authorized or entitled to enforce any rights, claims or remedies hereunder or by reason hereof.

 

Section
13.11 Other Instruments and Acts. The Members agree to execute any other instruments or perform any other acts that are or may
be necessary to effectuate and carry on the Company created by this Agreement.

 

Section
13.12 Remedies and Waivers. No delay or omission on the part of any party to this Agreement in exercising any right, power or
remedy provided by law or provided hereunder shall impair such right, power or remedy or operate as a waiver thereof. The single
or partial exercise of any right, power or remedy provided by law or provided hereunder shall not preclude any other or further
exercise of any other right, power or remedy. The rights, powers and remedies provided hereunder are cumulative and are not exclusive
of any rights, powers and remedies provided by law.

 

Section
13.13 Specific Performance. The parties hereto agree that irreparable damage would occur if any of the provisions of this Agreement
were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that the parties
shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms
and provisions hereof, in addition to any other remedy to which they are entitled at law or in equity.

 

    	 	38	 

     

    

 

Section
13.14 Public Announcements. No Member will issue any public announcements or disseminate any advertising or marketing material
concerning the existence or terms of this Agreement without the prior written approval of the Board of Managers, except to the
extent such announcement is required by law. If a public announcement is required by law, the Member required to make such disclosure
will consult with the Board of Managers before making the public announcement. To the extent any announcement or any advertising
or marketing material permitted under this Section 13.14 expressly refers to any Member or their Affiliates, such Member shall,
in its sole discretion, have the right to review and revise such announcement or advertising or marketing material prior to its
release. Notwithstanding anything to the contrary, this Section 13.14 shall not prevent any Member from communicating with limited
partners or prospective limited partners or investors of such Member or its Affiliates in connection with fundraising efforts
or reporting requirements.

 

Section
13.15 Competitive Activities. No Manager shall be required to manage the Company as his, her or its sole and exclusive function
and the Board of Managers, any Member of the Company and any of their respective Affiliates may have other business interests
and may engage in other activities in addition to those relating to the Company. Such other business interests or activities may
be of any nature or description, and may be engaged in independently or with others, and neither the Company nor any Member shall
have any right, by virtue of this Agreement or the Company relationship created hereby, in or to such other ventures or activities
of the Board of Managers or any other Member or any of their respective Affiliates, or to the income or proceeds derived therefrom,
and the pursuit of such ventures, even if competitive with the Company Business, shall not be deemed wrongful or improper.

 

Section
13.16 Roll-Up Transaction in Connection with an Initial Public Offering, Tag-Along Sale. Notwithstanding anything to the contrary
contained herein, in connection with the Initial Public Offering or a Tag-Along Sale, and upon the request of the Board of Managers,
each of the Members hereby agrees that it will, at the expense of the Company, take such action and execute such documents as
may reasonably be requested to effect such Initial Public Offering or Tag-Along Sale, including taking all such actions and executing
such documents as may reasonably be requested to convert the Company into a corporation or to contribute its respective Units
or other Equity Securities to a corporation, in each case substantially concurrently with the closing of the Initial Public Offering
or Tag-Along Sale, as applicable (a “Roll-Up Transaction”); provided, that, in connection with any Roll-Up Transaction,
the Members shall be entitled to receive that value of capital stock of the corporation whose shares of capital stock are being
sold in connection with such Initial Public Offering or Tag-Along Sale, as applicable, as equals the amount such Member would
be entitled to receive, relative to the Units or other Equity Securities which such Member held in the Company immediately prior
to such conversion or contribution, under Section 9.03 if a liquidation of the Company had occurred immediately prior to the consummation
of such Initial Public Offering or Tag-Along Sale, as applicable, with the proceeds in such liquidation equal in amount to the
implied aggregate equity valuation of such corporation immediately prior to the consummation of such Initial Public Offering or
Tag-Along Sale, as applicable; provided, further, that the shares of capital stock received by each such Member shall as nearly
as practicable provide the Member with the same economic and other rights, as such Member was entitled to prior to such conversion
or contribution.

 

    	 	39	 

     

    

 

Section
13.17 CONSENT TO JURISDICTION; SERVICE OF PROCESS AND VENUE. EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF
AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE DELAWARE COURT OF CHANCERY (OR, IF THAT COURT DOES NOT HAVE JURISDICTION,
TO THE SUPERIOR COURT OF NEW CASTLE COUNTY DELAWARE) AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN
RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH COURTS. EACH OF THE PARTIES HERETO AGREES THAT A
FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE
JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. EACH PARTY HEREBY WAIVES ANY RIGHT IT MAY HAVE TO ASSERT THE DOCTRINE OF FORUM
NON CONVENIENS OR SIMILAR DOCTRINE OR TO OBJECT TO VENUE WITH RESPECT TO ANY PROCEEDING BROUGHT IN ACCORDANCE WITH THIS SECTION,
AND STIPULATES THAT THE DELAWARE COURT OF CHANCERY (OR, IF THAT COURT DOES NOT HAVE JURISDICTION, THE SUPERIOR COURT OF NEW CASTLE
COUNTY DELAWARE) SHALL HAVE IN PERSONAM JURISDICTION AND VENUE OVER EACH OF THE PARTIES FOR THE PURPOSE OF LITIGATING ANY DISPUTE,
CONTROVERSY, OR PROCEEDING ARISING OUT OF OR RELATING IN ANY WAY WHATSOEVER TO THIS AGREEMENT. EACH PARTY HEREBY AUTHORIZES AND
AGREES TO ACCEPT SERVICE OF PROCESS SUFFICIENT FOR PERSONAL JURISDICTION IN ANY ACTION AGAINST IT AS CONTEMPLATED BY THIS SECTION
BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, POSTAGE PREPAID, TO ITS ADDRESS FOR THE GIVING OF NOTICES AS SET FORTH
IN THIS AGREEMENT.

 

[The
remainder of this page is intentionally left blank.]

 

    	 	40	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

	 	SYNCHEALTH
    MSO, LLC
	 	 	 
	 	MANAGERS:
	 	 	 
	 	By:	Alliance
    Pharma Solutions, LLC
	 	Its:	Manager
	 	 	 
	 	By:	 
    
	 	Name: 	Surendra
    Ajjarapu 
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	By:	PanOptic
    Health, LLC
	 	Its:	Manager
	 	 	 
	 	By:
    	
	 	Name: 	Meriam
    Ibrahim 
	 	Title:	Manager

 

Signature
Page To

Limited
Liability Company Agreement Of SyncHealth LLC

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

	 	MEMBERS:
	 	 	 
	 	Alliance
    Pharma Solutions, LLC
	 	 	 
	 	By:	 
	 	Name: 	Surendra
    Ajjarapu 
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	PANOPTIC
    HEALTH, LLC
	 	 	 
	 	By:	
	 	Name: 	Meriam
    Ibrahim 
	 	Title:	Manager

 

Signature
Page To

Limited
Liability Company Agreement Of Synchealth Llc

 

    	 	 	 

     

    

 

SCHEDULE
I

 

MEMBERS

 

The
following is as of 1 January 2019:

 

	Name
    of Member	 	Address	 	Capital
    Account	 	 	Number
    of Units	 
	 	 	 	 	 	 	 	 	 
	Alliance
    Pharma Solutions, LLC	 	3840
    Land O’ Lakes Blvd. 
 Land O’ Lakes, FL 34639 
 Attention: Suren Ajjarapu	 	$	250,000	 	 	 	300,000	 
	 	 	 	 	 	 	 	 	 	 	 
	PanOptic
    Health, LLC	 	2063
    Rancho Valley Dr., Suite 320-191 
 Pomona, CA 91766 
 ATTN: Meriam Ibrahim	 	$	100	 	 	 	700,000	 
	 	 	 	 	 	TOTAL	 	 	 	1,000,000	 

 

Schedule
I To

Limited
Liability Company Agreement Of Synchealth Llc

 

    	 	 	 

     

    

 

SCHEDULE
II

 

BOARD
OF MANAGERS

 

The
following is as of 1 January 2019:

 

Meriam
Ibrahim (PanOptic Manager)

 

Shawn
Patel (Alliance Manager)

 

TBD
(Independent Manager)

 

Schedule
II To

Limited
Liability Company Agreement Of Synchealth Llc

 

    	 	 	 

     

    

 

LIMITED
LIABILITY COMPANY AGREEMENT

 

OF

 

SYNCHEALTH
MSO, LLC

 

A
DELAWARE LIMITED LIABILITY COMPANY

 

Dated
as of 1 January 2019

 

THE
MEMBERSHIP INTERESTS AND UNITS REPRESENTED BY THIS SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH INTERESTS
MAY NOT BE SOLD, OFFERED, ASSIGNED, PLEDGED OR OTHERWISE DISPOSED OF AT ANY TIME WITHOUT EFFECTIVE REGISTRATION UNDER SUCH ACT
AND LAWS OR EXEMPTION THEREFROM, AND COMPLIANCE WITH THE OTHER SUBSTANTIAL RESTRICTIONS ON TRANSFER SET FORTH HEREIN.

 

SUCH
INTERESTS ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER SPECIFIED IN THIS AGREEMENT, AND THE COMPANY RESERVES THE RIGHT
TO REFUSE THE TRANSFER OF SUCH INTERESTS UNTIL SUCH CONDITIONS HAVE BEEN FULFILLED WITH RESPECT TO ANY TRANSFER.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]